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Preamble
These practice guidelines are intended to assist physicians in
clinical decision making by describing a range of generally
acceptable approaches for the diagnosis and management of
supraventricular arrhythmias. These guidelines attempt to
define practices that meet the needs of most patients in most
circumstances. The ultimate judgment regarding care of a
particular patient must be made by the physician and the
patient in light of all of the circumstances presented by that
patient. There are situations in which deviations from these
guidelines are appropriate.
I. Introduction
A. Organization of Committee and
Evidence Review
Supraventricular arrhythmias are a group of common rhythm
disturbances. The most common treatment strategies include
antiarrhythmic drug therapy and catheter ablation. Over the past
decade, the latter has been shown to be a highly successful and
often curative intervention. To facilitate and optimize the man-
agement of patients with supraventricular arrhythmias, the
American College of Cardiology Foundation (ACCF), the
American Heart Association (AHA), and the European Society
of Cardiology (ESC) created a committee to establish guidelines
for better management of these heterogeneous tachyarrhythmias.
This document summarizes the management of patients with
supraventricular arrhythmias with recommendations for diag-
nostic procedures as well as indications for antiarrhythmic drugs
and/or nonpharmacologic treatments.
Writing groups are specifically charged to perform a
formal literature review, weigh the strength of evidence for or
against a particular treatment or procedure, and include
estimates of expected health outcomes where data exist.
Patient-specific modifiers, comorbidities, and issues of pa-
tient preference that might influence the choice of particular
tests or therapies are considered, as are frequency of
follow-up and cost effectiveness. In controversial areas, or
with regard to issues without evidence other than usual
clinical practice, a consensus was achieved by agreement of
the expert panel after thorough deliberations.
This document was peer reviewed by two official external
reviewers representing the American College of Cardiology
Foundation, two official external reviewers representing the
American Heart Association, and two official external re-
viewers representing the European Society of Cardiology.
The North American Society for Pacing and Electrophysiol-
ogy—Heart Rhythm Society assigned one organizational
reviewer to the guideline. In addition, 37 external content
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reviewers participated in the review representing the ACC/
AHA Task Force on Practice Guidelines, the ESC Committee
for Practice Guidelines, the ACCF Electrophysiology Com-
mittee, the AHA ECG/Arrhythmias Committee, the ESC
Working Group on Arrhythmias, and the ESC Task Force on
Grown-Up Congenital Heart Disease. Please see Appendix 2
in the full-text guideline for the names of all reviewers.
The document was approved for publication by the gov-
erning bodies of the ACCF, AHA, and ESC. These guidelines
will be reviewed annually by the ESC and the ACC/AHA
Task Force on Practice Guidelines and will be considered
current unless they are revised or withdrawn from
distribution.
Recommendations are evidence-based and derived primar-
ily from published data. The level of evidence was ranked as
follows:
Level A (highest): derived from multiple randomized clinical
trials;
Level B (intermediate): data are on the basis of a limited
number of randomized trials, nonrandomized studies, or
observational registries;
Level C (lowest): primary basis for the recommendation was
expert consensus.
Recommendations follow the format of previous ACC/
AHA guidelines for classifying indications, summarizing
both the evidence and expert opinion.
Class I: Conditions for which there is evidence for and/or
general agreement that the procedure or treatment
is useful and effective.
Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the useful-
ness/efficacy of a procedure or treatment.
Class IIa: The weight of evidence or opinion is
in favor of the procedure or treatment.
Class IIb: Usefulness/efficacy is less well estab-
lished by evidence or opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure or treatment
is not useful/effective and in some cases may be
harmful.
B. Contents of these Guidelines—Scope
The purpose of this joint ACC/AHA/ESC document is to
provide clinicians with practical and authoritative guidelines
for the management and treatment of patients with supraven-
tricular arrhythmias (SVA). These include rhythms emanat-
ing from the sinus node, from atrial tissue (atrial flutter), and
from junctional as well as reciprocating or accessory path-
way–mediated tachycardia. This document does not include
recommendations for patients with either atrial fibrillation
(AF) (see ACC/AHA/ESC Guidelines for the Management of
Patients With Atrial Fibrillation (1)) or for pediatric patients
with supraventricular arrhythmias. For our purposes, the term
“supraventricular arrhythmia” refers to all types of supraven-
tricular arrhythmias, excluding AF, as opposed to SVT,
which includes atrioventricular nodal reciprocating
tachycardia (AVNRT), atrioventricular reciprocating
tachycardia (AVRT), and atrial tachycardia (AT).
Overall, this is a consensus document that includes evi-
dence and expert opinions from several countries. The phar-
macologic and nonpharmacologic antiarrhythmic approaches
discussed may, therefore, include some drugs and devices
that do not have the approval of governmental regulatory
agencies. Because antiarrhythmic drug dosages and drug
half-lives are detailed in the ACC/AHA/ESC Guidelines for
the Management of Patients With Atrial Fibrillation (1), they
are not repeated in this document.
II. Public Health Considerations
and Epidemiology
Supraventricular arrhythmias are relatively common, often
repetitive, occasionally persistent, and rarely life threatening.
The precipitants of supraventricular arrhythmias vary with
age, sex, and associated comorbidity (2).
Failure to discriminate among AF, atrial flutter, and other
supraventricular arrhythmias has complicated the precise
definition of this arrhythmia in the general population. The
estimated prevalence of paroxysmal supraventricular
tachycardia (PSVT) in a 3.5% sample of medical records in
the Marshfield (Wisconsin) Epidemiologic Study Area
(MESA) was 2.25 per 1000 (3). The incidence of PSVT in
this survey was 35 per 100 000 person-years (3).
Age exerts an influence on the occurrence of SVT. The
mean age at the time of PSVT onset in the MESA cohort was
57 years (ranging from infancy to more than 90 years old) (3).
In the MESA population, compared with those with other
cardiovascular disease, “lone” (no cardiac structural disease)
PSVT patients were younger (mean age equals 37 versus 69
years), had faster heart rates (186 versus 155 beats per minute
[bpm]), and were more likely to present first to an emergency
room (69% versus 30%) (3). The age of tachycardia onset is
higher for AVNRT (32 plus or minus 18 years) than for
AVRT (23 plus or minus 14 years).
Gender plays a role in the epidemiology of SVT. Female
residents in the MESA population had a twofold greater
relative risk (RR) of PSVT (RR equals 2.0; 95% confidence
interval equals 1.0 to 4.2) compared with males (3).
The only reported epidemiologic study of patients with
atrial flutter (4) involved a selected sample of individuals
treated in the Marshfield Clinic in predominantly white, rural
mid-Wisconsin. More than 75% of the 58 820 residents and
virtually all health events were included in this population
database. In approximately 60% of cases, atrial flutter oc-
curred for the first time in association with a specific
precipitating event (ie, major surgery, pneumonia, or acute
myocardial infarction). In the remaining patients, atrial flutter
was associated with chronic comorbid conditions (ie, heart
failure, hypertension, and chronic lung disease). Only 1.7%
of cases had no structural cardiac disease or precipitating
causes (lone atrial flutter). The overall incidence of atrial
flutter was 0.088%; 58% of these patients also had AF. Atrial
flutter alone was seen in 0.037%. The incidence of atrial
flutter increased markedly with age, from 5 per 100 000 of
those more than 50 years old to 587 per 100 000 over age 80.
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Atrial flutter was 2.5 times more common in men and was
diagnosed twice as often as PSVT.
III. General Mechanisms of SVA
A. Specialized Atrial Tissue
The sinoatrial node, atria, and atrioventricular (AV) node are
heterogeneous structures. There is distinct electrophysiolog-
ical specialization of tissues and cells within these structures.
In the case of the nodes, cellular heterogeneity is a prominent
feature.
The sinoatrial node is a collection of morphologically and
electrically distinct cells (5,6). The central portion of the
sinus node, which houses the dominant pacemaking function,
contains cells with longer action potentials and faster rates of
phase 4 diastolic depolarization than other cardiac cells (6,7).
Cellular recordings support the existence of distinct popu-
lations of cells in the mammalian AV node. Differences in ion
channel expression underlie the differences in the electro-
physiological behavior of each of the cell types.
B. General Mechanisms
All cardiac tachyarrhythmias are produced by one or more
mechanisms, including disorders of impulse initiation and
abnormalities of impulse conduction. The former are often
referred to as automatic, and the latter as re-entrant. Tissues
exhibiting abnormal automaticity that underlie SVT can
reside in the atria, the AV junction, or vessels that commu-
nicate directly with the atria, such as the vena cava or
pulmonary veins (8,9). The cells with enhanced automaticity
exhibit enhanced diastolic phase 4 depolarization and, there-
fore, an increase in firing rate compared with pacemaker
cells. If the firing rate of the ectopic focus exceeds that of the
sinus node, then the sinus node can be overdriven and the
ectopic focus will become the predominant pacemaker of the
heart. The rapid firing rate may be incessant (ie, more than
50% of the day) or episodic.
Triggered activity is a tachycardia mechanism associated
with disturbances of recovery or repolarization. Triggered
rhythms are generated by interruptions in repolarization of a
heart cell called afterdepolarizations. An afterdepolarization
of sufficient magnitude may reach “threshold” and trigger an
early action potential during repolarization.
The most common arrhythmia mechanism is re-entry,
which may occur in different forms. In its simplest form, it
occurs as repetitive excitation of a region of the heart and is
a result of conduction of an electrical impulse around a fixed
obstacle in a defined circuit. This is referred to as re-entrant
tachycardia. There are several requirements for the initiation
and maintenance of this type of re-entry. Initiation of a circus
movement tachycardia requires unidirectional conduction
block in one limb of a circuit. Unidirectional block may occur
as a result of acceleration of the heart rate or block of a
premature impulse that impinges on the refractory period of
the pathway. Slow conduction is usually required for both
initiation and maintenance of a circus movement tachycardia.
In the case of orthodromic AV re-entry (ie, anterograde
conduction across the AV node with retrograde conduction
over an accessory pathway), slowed conduction through the
AV node allows for recovery of, and retrograde activation
over, the accessory pathway.
Re-entry is the mechanism of tachycardia in SVTs such as
AVRT, AVNRT and atrial flutter; however, a fixed obstacle
and predetermined circuit are not essential requirements for
all forms of re-entry. In functionally determined re-entry,
propagation occurs through relatively refractory tissue and
there is an absence of a fully excitable gap. Specific mecha-
nisms are considered in the following sections.
IV. Clinical Presentation, General Evaluation,
and Management of Patients With SVA
A. General Evaluation of Patients Without
Documented Arrhythmia
1. Clinical History and Physical Examination
Patients with paroxysmal arrhythmias are most often asymp-
tomatic at the time of evaluation. Arrhythmia-related symp-
toms include palpitations; fatigue; lightheadedness; chest
discomfort; dyspnea; presyncope; or, more rarely, syncope.
A history of arrhythmia-related symptoms may yield impor-
tant clues to the type of arrhythmia. Premature beats are
commonly described as pauses or nonconducted beats followed
by a sensation of a strong heart beat, or they are described as
irregularities in heart rhythm. Supraventricular tachycardias
occur in all age groups and may be associated with minimal
symptoms, such as palpitations, or they may present with
syncope. The clinician should distinguish whether the palpita-
tions are regular or irregular. Irregular palpitations may be due to
premature depolarizations, AF, or multifocal atrial tachycardia
(MAT). The latter are most commonly encountered in patients
with pulmonary disease. If the arrhythmia is recurrent and has
abrupt onset and termination, then it is designated paroxysmal.
Sinus tachycardia is, conversely, nonparoxysmal and accelerates
and terminates gradually. Patients with sinus tachycardia may
require evaluation for stressors, such as infection or volume loss.
Episodes of regular and paroxysmal palpitations with a sudden
onset and termination (also referred to as PSVT) most com-
monly result from AVRT or AVNRT. Termination by vagal
maneuvers further suggests a re-entrant tachycardia involving
AV nodal tissue (eg, AVNRT, AVRT). Polyuria is caused by
release of atrial natriuretic peptide in response to increased atrial
pressures from contraction of atria against a closed AV valve,
which is supportive of a sustained supraventricular arrhythmia.
With SVT, syncope is observed in approximately 15% of
patients, usually just after initiation of rapid SVT or with a
prolonged pause after abrupt termination of the tachycardia.
Syncope may be associated with AF with rapid conduction
over an accessory AV pathway or may suggest concomitant
structural abnormalities, such as valvular aortic stenosis,
hypertrophic cardiomyopathy, or cerebrovascular disease.
Symptoms vary with the ventricular rate, underlying heart
disease, duration of SVT, and individual patient perceptions.
Supraventricular tachycardia that is persistent for weeks to
months and associated with a fast ventricular response may
lead to a tachycardia-mediated cardiomyopathy (10,11).
Of crucial importance in clinical decision making is a clinical
history describing the pattern in terms of the number of episodes,
duration, frequency, mode of onset, and possible triggers.
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Supraventricular tachycardia has a heterogeneous clinical
presentation, most often occurring in the absence of detect-
able heart disease in younger individuals. The presence of
associated heart disease should nevertheless always be
sought, and an echocardiogram may be helpful. While a
physical examination during tachycardia is standard, it usu-
ally does not lead to a definitive diagnosis. If irregular cannon
A waves and/or irregular variation in S1 intensity is present,
then a ventricular origin of a regular tachycardia is strongly
suggested.
2. Diagnostic Investigations
A resting 12-lead echocardiogram (ECG) should be recorded.
The presence of pre-excitation on the resting ECG in a patient
with a history of paroxysmal regular palpitations is sufficient for
the presumptive diagnosis of AVRT, and attempts to record
spontaneous episodes are not required before referral to an
arrhythmia specialist for therapy (Figure 1). Specific therapy is
discussed in Section V. A clinical history of irregular and
paroxysmal palpitations in a patient with baseline pre-excitation
strongly suggests episodes of AF, which requires immediate
electrophysiological evaluation because these patients are at risk
for significant morbidity and possibly sudden death (see Section
V-D). The diagnosis is otherwise made by careful analysis of the
12-lead ECG during tachycardia (see Section IV). Therefore,
patients with a history of sustained arrhythmia should always be
encouraged to have at least one 12-lead ECG taken during the
arrhythmia. Automatic analysis systems of 12-lead ECGs are
unreliable and commonly suggest an incorrect arrhythmia
diagnosis.
Indications for referral to a cardiac arrhythmia specialist
include presence of a wide complex tachycardia of unknown
origin. For those with narrow complex tachycardias, referral
is indicated for those with drug resistance or intolerance as
well as for patients desiring to be free of drug therapy.
Because of the potential for lethal arrhythmias, all patients
with the Wolff-Parkinson-White (WPW) syndrome (ie, pre-
excitation combined with arrhythmias) should be referred for
further evaluation. All patients with severe symptoms, such
as syncope or dyspnea, during palpitations should also be
referred for prompt evaluation by an arrhythmia specialist.
An echocardiographic examination should be considered in
patients with documented sustained SVT to exclude the
possibility of structural heart disease, which usually cannot be
detected by physical examination or 12-lead ECG.
An ambulatory 24-hour Holter recording can be used in
patients with frequent (ie, several episodes per week) but
transient tachycardias (12). An event or wearable loop recorder
is often more useful than a 24-hour recording in patients with
less frequent arrhythmias. Implantable loop recorders may be
helpful in selected cases with rare symptoms (ie, fewer than two
episodes per month) associated with severe symptoms of hemo-
dynamic instability (13). Exercise testing is less often useful for
diagnosis unless the arrhythmia is clearly triggered by exertion.
Transesophageal atrial recordings and stimulation may be
used in selected cases for diagnosis or to provoke paroxysmal
tachyarrhythmias if the clinical history is insufficient or if
other measures have failed to document an arrhythmia.
Esophageal stimulation is not indicated if invasive electro-
physiological investigation is planned. Invasive electrophys-
iological investigation with subsequent catheter ablation may
be used for diagnoses and therapy in cases with a clear history
of paroxysmal regular palpitations. It may also be used
Figure 1. Initial evaluation of patients
with suspected tachycardia. AVRT indi-
cates atrioventricular reciprocating
tachycardia.
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empirically in the presence of pre-excitation or disabling
symptoms (Figure 1).
3. Management
The management of patients with symptoms suggestive of an
arrhythmia but without ECG documentation depends on the
nature of the symptoms. If the surface ECG is normal and the
patient reports a history consistent with premature extra beats,
then precipitating factors, such as excessive caffeine, alcohol,
nicotine intake, recreational drugs, or hyperthyroidism, should
be reviewed and eliminated. Benign extrasystoles are often
manifest at rest and tend to become less common with exercise.
If symptoms and the clinical history indicate that the
arrhythmia is paroxysmal in nature and the resting 12-lead
ECG gives no clue for the arrhythmia mechanism, then
further diagnostic tests for documentation may not be neces-
sary before referral for an invasive electrophysiological study
and/or catheter ablation. Patients should be taught to perform
vagal maneuvers. A beta-blocking agent may be prescribed
empirically provided that significant bradycardia (less than
50 bpm) have been excluded. Due to the risk of proarrhyth-
mia, antiarrhythmic treatment with class I or class III drugs
should not be initiated without a documented arrhythmia.
B. General Evaluation of Patients With
Documented Arrhythmia
1. Diagnostic Evaluation
Whenever possible, a 12-lead ECG should be taken during
tachycardia but should not delay immediate therapy to termi-
nate the arrhythmia if there is hemodynamic instability. At a
minimum, a monitor strip should be obtained from the
defibrillator, even in cases with cardiogenic shock or cardiac
arrest, before direct current (DC) cardioversion is applied to
terminate the arrhythmia.
a. Differential Diagnosis for Narrow
QRS-Complex Tachycardia
If ventricular action (QRS) is narrow (less than 120 ms), then
the tachycardia is almost always supraventricular and the
differential diagnosis relates to its mechanism (Figure 2). If
no P waves or evidence of atrial activity is apparent and the
RR interval is regular, then AVNRT is most commonly the
mechanism. P-wave activity in AVNRT may be only partially
hidden within the QRS complex and may deform the QRS to
give a pseudo–R wave in lead V1 and/or a pseudo–S wave in
inferior leads (Figure 3). If a P wave is present in the ST
segment and separated from the QRS by 70 ms, then AVRT
is most likely. In tachycardias with RP longer than PR, the
most likely diagnosis is atypical AVNRT, permanent form of
junctional reciprocating tachycardia (PJRT) (ie, AVRT via a
slowly conducting accessory pathway), or AT (see Section V-B, D,
and E). Responses of narrow QRS-complex tachycardias to
adenosine or carotid massage may aid in the differential
diagnosis (Figure 4) (14,15). A 12-lead ECG recording is
desirable during use of adenosine or carotid massage. If P
waves are not visible, then the use of esophageal pill
electrodes can also be helpful.
Figure 2. Differential diagnosis for narrow QRS tachycardia. Patients with focal junctional tachycardia may mimic the pattern of slow–
fast AVNRT and may show AV dissociation and/or marked irregularity in the junctional rate. AV indicates atrioventricular; AVNRT, atrio-
ventricular nodal reciprocating tachycardia; AVRT, atrioventricular reciprocating tachycardia; MAT, multifocal atrial tachycardia; ms, mil-
liseconds; PJRT, permanent form of junctional reciprocating tachycardia; QRS, ventricular activation on ECG.
1498 Blomström-Lundqvist et al. JACC Vol. 42, No. 8, 2003
ACC/AHA/ESC Guidelines for Management of SVA October 15, 2003:1493–531
b. Differential Diagnosis for Wide
QRS-Complex Tachycardia
If the QRS is wide (more than 120 ms), then it is important to
differentiate between SVT and ventricular tachycardia (VT)
(Figure 5). Intravenous medications given for the treatment of
SVT, particularly verapamil or diltiazem, may be deleterious
because they may precipitate hemodynamic collapse for a
patient with VT. Stable vital signs during tachycardias are not
helpful for distinguishing SVT from VT. If the diagnosis of
SVT cannot be proven or cannot be made easily, then the
patient should be treated as if VT were present. Wide QRS
tachycardia can be divided into three groups: SVT with
bundle-branch block (BBB) or aberration, SVT with AV
conduction over an accessory pathway, and VT.
(1) Supraventricular Tachycardia With Bundle-Branch
Block. Bundle-branch block may be pre-existing or may
occur only during tachycardia when one of the bundle
branches is refractory due to the rapid rate. Most BBBs
are not only rate-related but are also due to a long-short
sequence of initiation. Bundle-branch block can occur
with any supraventricular arrhythmia. If a rate-related
BBB develops during orthodromic AVRT, then the
tachycardia rate may slow if the BBB is ipsilateral to the
bypass tract location.
(2) Supraventricular Tachycardia With Atrioventricular
Conduction Over an Accessory Pathway. Supraventricu-
lar tachycardia with AV conduction over an accessory
pathway may occur during AT, atrial flutter, AF,
AVNRT, or antidromic AVRT. The latter is defined as
anterograde conduction over the accessory pathway and
retrograde conduction over the AV node or a second
accessory AV pathway. A wide-QRS complex with left
bundle-branch block (LBBB) morphology may be seen
with anterograde conduction over other types of acces-
sory pathways, such as atriofascicular, nodofascicular, or
nodoventricular tracts.
(3) Ventricular Tachycardia. Several ECG criteria have been
described to differentiate the underlying mechanism of a
wide-QRS tachycardia.
(i) VENTRICULAR ARRHYTHMIA (VA) DISSOCIATION. VA
dissociation with a ventricular rate faster than the
Figure 3. ECG pattern of typical AVNRT. Panel A: 12-Lead ECG shows a regular SVT recorded at an ECG paper speed of 25 mm/sec.
Panel B: After conversion to sinus rhythm, the 12-lead ECG shows sinus rhythm with narrow QRS complexes. In comparison with
Panel A: Note the pseudo r in V1 (arrow) and accentuated S waves in 2, 3, aVF (arrow). These findings are pathognomonic for AVNRT.
AVNRT indicates atrioventricular nodal reciprocating tachycardia; mm/sec, millimeters per second; QRS, ventricular activation on ECG;
SVT, supraventricular tachycardia; VF, ventricular fibrillation.
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atrial rate generally proves the diagnosis of VT
(Figures 5 and 6) but is clearly discernible in only
30% of all VTs. Fusion complexes represent a
merger between conducted sinus (or supraventricu-
lar complexes) impulses and ventricular depolariza-
tion occurring during AV dissociation. These com-
plexes are pathognomonic of VT. Retrograde VA
block may be present spontaneously or brought out
by carotid massage. The demonstration that P waves
are not necessary for tachycardia maintenance
strongly suggests VT. P waves can be difficult to
recognize during a wide-QRS tachycardia. There-
fore, one should also look for evidence of VA
dissociation on physical examination: irregular can-
non A waves in the jugular venous pulse and
variability in the loudness of the first heart sound
and in systolic blood pressure. If P waves are not
visible, then the use of esophageal pill electrodes
can also be useful.
(ii) WIDTH OF THE QRS COMPLEX. A QRS width of more
than 0.14 seconds with right bundle-branch block
(RBBB) or 0.16 seconds during LBBB pattern
favors VT. The QRS width criteria are not helpful
for differentiating VT from SVT with AV conduc-
tion over an accessory pathway. A patient with SVT
can have a QRS width of more than 0.14 (RBBB) or
0.16 (LBBB) in the presence of either pre-existing
BBB or AV conduction over an accessory pathway
or when class Ic or class Ia antiarrhythmic drugs are
used.
(iii) CONFIGURATIONAL CHARACTERISTICS OF THE QRS
COMPLEX DURING TACHYCARDIA. Leads V1 and V6
are helpful in differentiating VT from SVT.
● An RS (from the initial R to the nadir of S) interval longer
than 100 ms in any precordial lead is highly suggestive of
VT.
● A QRS pattern with negative concordance in the precordial
leads is diagnostic for VT (“negative concordance” means
that the QRS patterns in all of the precordial leads are
similar, and with QS complexes). Positive concordance
does not exclude antidromic AVRT over a left posterior
accessory pathway.
● The presence of ventricular fusion beats indicates a ven-
tricular origin of the tachycardia.
● QR complexes indicate a myocardial scar and are present in
approximately 40% of patients with VTs after myocardial
infarction.
The width and morphological criteria are less specific for
patients taking certain antiarrhythmic agents and those with
hyperkalemia or severe heart failure. Despite ECG criteria,
patients presenting with wide QRS-complex tachycardia are
often misdiagnosed. A positive answer to two inquiries,
namely the presence of a previous myocardial infarct and the
first occurrence of a wide QRS-complex tachycardia after an
infarct, strongly indicates a diagnosis of VT.
2. Management
When a definitive diagnosis can be made on the basis of ECG
and clinical criteria, acute and chronic treatment should be
initiated on the basis of the underlying mechanism (see
sections on specific arrhythmias).
If the specific diagnosis of a wide QRS-complex
tachycardia cannot be made despite careful evaluation, then
the patient should be treated for VT. Acute management of
patients with hemodynamically stable and regular tachycardia
is outlined in Figure 7.
The most effective and rapid means of terminating any
hemodynamically unstable narrow or wide QRS-complex
tachycardia is DC cardioversion.
a. Acute Management of Narrow
QRS-Complex Tachycardia
In regular narrow QRS-complex tachycardia, vagal maneu-
vers (ie, Valsalva, carotid massage, and facial immersion in
cold water) should be initiated to terminate the arrhythmia or
to modify AV conduction. If this fails, then intravenous (IV)
antiarrhythmic drugs should be administered for arrhythmia
Figure 4. Responses of narrow complex tachycardias to adenosine. AT indicates atrial tachycardia; AV, atrioventricular; AVNRT, atrio-
ventricular nodal reciprocating tachycardia; AVRT, atrioventricular reciprocating tachycardia; IV, intravenous; QRS, ventricular activation
on ECG; VT, ventricular tachycardia.
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termination in hemodynamically stable patients. Adenosine
(or adenosine triphosphate [ATP]) or nondihydropyridine
calcium-channel antagonists are the drugs of choice (Figure
4). The advantage of adenosine relative to IV calcium-
channel or beta blockers relates to its rapid onset and short
half-life. Intravenous adenosine is, therefore, the preferred
agent except for patients with severe asthma. Patients treated
with theophylline may require higher doses of adenosine for
effect, and adenosine effects are potentiated by dipyridamole.
In addition, higher rates of heart block may be seen when
adenosine is concomitantly administered with carbamaz-
epine. Longer-acting agents (eg, IV calcium-channel blockers
or beta blockers [ie, verapamil/diltiazem or metoprolol]) are
of value, particularly for patients with frequent atrial prema-
ture beats or ventricular premature beats, which may serve to
trigger early recurrence of PSVT. Adenosine or DC cardio-
version is preferred for those with PSVT in whom a rapid
therapeutic effect is essential. Potential adverse effects of
adenosine include initiation of AF (1% to 15%), which is
usually transient and may be particularly problematic for
those with ventricular pre-excitation. Adenosine should be
avoided in patients with severe bronchial asthma. It is
important to use extreme care with concomitant use of IV
calcium-channel blockers and beta blockers because of pos-
sible potentiation of hypotensive and/or bradycardic effects.
An ECG should be recorded during vagal maneuvers or drug
administration because the response may aid in the diagnosis
even if the arrhythmia does not terminate (Figure 4). Termi-
nation of the tachycardia with a P wave after the last QRS
complex favors a diagnosis of AVRT or AVNRT.
Tachycardia termination with a QRS complex favors AT,
which is often adenosine insensitive. Continuation of
tachycardia with AV block is virtually diagnostic of AT or
atrial flutter, excludes AVRT, and makes AVNRT very unlikely.
Figure 5. Differential diagnosis for wide QRS-complex tachycardia (more than 120 ms). A QRS conduction delay during sinus rhythm,
when available for comparison, reduces the value of QRS morphology analysis. Adenosine should be used with caution when the diag-
nosis is unclear because it may produce VF in patients with coronary artery disease and AF with a rapid ventricular rate in pre-excited
tachycardias. Various adenosine responses are shown in Figure 4. *Concordant indicates that all precordial leads show either positive
or negative deflections. Fusion complexes are diagnostic of VT. †In pre-excited tachycardias, the QRS is generally wider (ie, more pre-
excited) compared with sinus rhythm. A indicates atrial; AP, accessory pathway; AT, atrial tachycardia; AV, atrioventricular; AVRT, atrio-
ventricular reciprocating tachycardia; BBB, bundle-branch block; LBBB, left bundle-branch block; ms, milliseconds; QRS, ventricular
activation on ECG; RBBB, right bundle-branch block; SR, sinus rhythm; SVT, supraventricular tachycardias; V, ventricular; VF, ventricu-
lar fibrillation; VT, ventricular tachycardia.
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b. Acute Management of Wide QRS-Complex Tachycardia
Immediate DC cardioversion is the treatment for hemody-
namically unstable tachycardias. If the tachycardia is hemo-
dynamically stable and definitely supraventricular, then man-
agement is as described for narrow QRS tachycardias (Figure
4). For pharmacologic termination of a stable wide QRS-
complex tachycardia, IV procainamide and/or sotalol are
recommended on the basis of randomized but small studies.
Amiodarone is also considered acceptable. Amiodarone is
preferred compared with procainamide and sotalol for pa-
tients with impaired left ventricular (LV) function or signs of
heart failure. These recommendations are in accord with the
current Advanced Cardiovascular Life Support guidelines
(16). Special circumstances may require alternative therapy
(ie, pre-excited tachycardias and VT caused by digitalis
toxicity). For termination of an irregular wide QRS-complex
tachycardia (ie, pre-excited AF), DC cardioversion is recom-
mended. Or, if the patient is hemodynamically stable, then
pharmacologic conversion using IV ibutilide or flecainide is
appropriate.
c. Further Management
After successful termination of a wide QRS-complex
tachycardia of unknown etiology, patients should be referred
to an arrhythmia specialist. Patients with stable narrow
QRS-complex tachycardia, normal LV function, and a normal
ECG during sinus rhythm (ie, no pre-excitation) may require
no specific therapy. Referral is indicated for those with drug
resistance or intolerance as well as for patients desiring to be
free of lifelong drug therapy. When treatment is indicated,
options include catheter ablation or drug therapy. Finally,
because of the potential for lethal arrhythmias, all patients
with WPW syndrome (ie, pre-excitation and arrhythmias)
should be referred for further evaluation. Table 1 lists
recommendations for acute management of hemodynamically
stable and regular tachycardia.
V. Specific Arrhythmias
A. Sinus Tachyarrhythmias
Sinus tachycardia usually occurs in response to an appropri-
ate physiological stimulus (eg, exercise) or to an excessive
stimulus (eg, hyperthyroidism). Failure of the mechanisms
that control the sinus rate may lead to an inappropriate sinus
tachycardia. Excessive sinus tachycardia may also occur in
response to upright posture (postural orthostatic tachycardia
syndrome [POTS]). A re-entry mechanism may also occur
within or close to the sinus node, resulting in so-called sinus
node re-entrant tachycardia, which is also sometimes known
as sinoatrial re-entry.
1. Physiological Sinus Tachycardia
The normally innervated sinus node generates an impulse
approximately 60 to 90 times per minute and responds to
autonomic influences. Nevertheless, the sinus node is a
versatile structure and is influenced by many other factors,
including hypoxia, acidosis, stretch, temperature, and hor-
mones (eg, tri-iodothyronine, serotonin).
a. Definition
Sinus tachycardia is defined as an increase in sinus rate to
more than 100 bpm in keeping with the level of physical,
emotional, pathological, or pharmacologic stress. Pathologi-
cal causes of sinus tachycardia include pyrexia, hypovolemia,
or anemia, which may result from infections. Drugs that
induce sinus tachycardia include stimulants (eg, caffeine,
alcohol, nicotine); prescribed compounds (eg, salbutamol,
aminophylline, atropine, catecholamines); and certain recre-
ational/illicit drugs (eg, amphetamines, cocaine, “ecstasy,”
cannabis) (33). Anticancer treatments, in particular anthracy-
cline compounds such as doxorubicin (or Adriamycin) and
daunorubicin, can also trigger sinus tachycardia as part of the
acute cardiotoxic response that is predominantly catechol-
amine/histamine induced (34) or part of a late cardiotoxic
response. Sinus tachycardia may signal severe underlying
pathologies and often requires comprehensive evaluation.
Atrial and sinus tachycardias may be difficult to differentiate.
b. Mechanism
Sinus tachycardia results from physiological influences on
individual pacemaker cells and from an anatomical shift in
the site of origin of atrial depolarization superiorly within the
sinus node.
c. Diagnosis
In normal sinus rhythm, the P wave on a 12-lead ECG is
positive in leads I, II, and aVF and negative in aVR. Its axis
in the frontal plane lies between 0 and 90; in the horizontal
plane, it is directed anteriorly and slightly leftward and can,
therefore, be negative in leads V1 and V2 but positive in leads
V3 to V6. The P waves have a normal contour, but a larger
amplitude may develop and the wave may become peaked
Figure 6. Electrocardiogram showing AV dissociation during VT
in a patient with a wide QRS-complex tachycardia. The P waves
are marked with arrows.
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(35). Sinus tachycardia is nonparoxysmal, thus differentiating
it from re-entry.
d. Treatment
The mainstay in the management of sinus tachycardias
primarily involves identifying the cause and either eliminat-
ing or treating it. Beta blockade, however, can be extremely
useful and effective for physiological symptomatic sinus
tachycardia triggered by emotional stress and other anxiety-
related disorders (36–38); for prognostic benefit after myo-
cardial infarction (39); for the symptomatic and prognostic
benefits in certain other irreversible causes of sinus
tachycardias, such as congestive cardiac failure (40,41); and
for symptomatic thyrotoxicosis in combination with carbima-
zole or propylthiouracyl while these palliative agents take
effect (42). Nondihydropyridine calcium-channel blockers,
such as dilitiazem or verapamil, may be of benefit in patients
with symptomatic thyrotoxicosis if beta blockade is
contraindicated.
2. Inappropriate Sinus Tachycardia
a. Definition
Inappropriate sinus tachycardia is a persistent increase in
resting heart rate or sinus rate unrelated to, or out of
Figure 7. Acute management of patients with hemodynamically stable and regular tachycardia. *A 12-lead ECG during sinus rhythm
must be available for diagnosis. †Adenosine should be used with caution in patients with severe coronary artery disease and may pro-
duce AF, which may result in rapid ventricular rates for patients with pre-excitation. **Ibutilide is especially effective for patients with
atrial flutter but should not be used in patients with EF less than 30% due to increased risk of polymorphic VT. AF indicates atrial fibril-
lation; AV, atrioventricular; BBB, bundle-branch block; DC, direct current; IV, intravenous; LV, left ventricle; QRS, ventricular activation
on ECG; SVT, supraventricular tachycardia; VT, ventricular tachycardia.
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proportion with, the level of physical, emotional, pathologi-
cal, or pharmacologic stress.
b. Mechanism
The underlying pathological basis for inappropriate sinus
tachycardia is likely to be multifactorial, but two main
mechanisms have been proposed:
1. Enhanced automaticity of the sinus node
2. Abnormal autonomic regulation of the sinus node with
excess sympathetic and reduced parasympathetic tone.
c. Presentation
A high proportion of patients with inappropriate sinus
tachycardia are healthcare professionals, and approximately
90% are female. The mean age of presentation is 38 plus or
minus 12 years. Although the predominant symptom at
presentation is that of palpitations, symptoms such as chest
pain, shortness of breath, dizziness, lightheadedness, and
pre-syncope have also been reported. The degree of disability
can vary tremendously, from totally asymptomatic patients
identified during routine medical examination to individuals
who are fully incapacitated. Clinical examination and routine
investigations allow elimination of a secondary cause for the
tachycardia but are generally not helpful in establishing the
diagnosis.
d. Diagnosis
Sinus tachycardia is diagnosed on the basis of invasive and
noninvasive criteria (43):
1. The presence of a persistent sinus tachycardia (heart
rate more than 100 bpm) during the day with excessive
rate increase in response to activity and nocturnal
TABLE 1. Recommendations for Acute Management of Hemodynamically Stable and Regular Tachycardia
ECG Recommendation* Classification Level of Evidence References
Narrow QRS-complex tachycardia (SVT) Vagal maneuvers I B
Adenosine I A 15,17,18
Verapamil, diltiazem I A 19
Beta blockers IIb C 20,21
Amiodarone IIb C 22
Digoxin IIb C
Wide QRS-complex tachycardia
● SVT  BBB See above
● Pre-excited SVT/AF† Flecainide‡ I B 23
Ibutilide‡ I B 24
Procainamide‡ I B
DC cardioversion I C
● Wide QRS-complex tachycardia of unknown Procainamide‡ I B 25,26
origin Sotalol‡ I B 27
Amiodarone I B 29,30
DC cardioversion I B 28
Lidocaine IIb B 26,27
Adenosine§ IIb C 31
Beta blockers¶ III C 28
Verapamil** III B 32
Wide QRS-complex tachycardia of unknown Amiodarone I B 29,30
origin in patients with poor LV function DC cardioversion, lidocaine I B 28
The order in which treatment recommendations appear in this table within each class of recommendation does not necessarily
reflect a preferred sequence of administration. Please refer to text for details. For pertinent drug dosing information please refer to
the ACC/AHA/ESC Guidelines on the Management of Patients With Atrial Fibrillation.
*All listed drugs are administered intravenously.
†See Section V-D.
‡Should not be taken by patients with reduced LV function.
§Adenosine should be used with caution in patients with severe coronary artery disease because vasodilation of normal coronary
vessels may produce ischemia in vulnerable territory. It should be used only with full resuscitative equipment available.
¶Beta blockers may be used as first-line therapy for those with catecholamine-sensitive tachycardias, such as right ventricular
outflow tachycardia.
**Verapamil may be used as first-line therapy for those with LV fascicular VT.
AF indicates atrial fibrillation; BBB, bundle-branch block; DC, direct current; ECG, electrocardiogram; LV, left ventricular; QRS,
ventricular activation on ECG; SVT, supraventricular tachycardia; VT, ventricular tachycardia.
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normalization of rate as confirmed by a 24-hour Holter
recording
2. The tachycardia (and symptoms) is nonparoxysmal
3. P-wave morphology and endocardial activation identical
to sinus rhythm
4. Exclusion of a secondary systemic cause (eg, hyperthy-
roidism, pheochromocytoma, physical deconditioning)
e. Treatment
The treatment of inappropriate sinus tachycardia is predom-
inantly symptom driven. The risk of tachycardia-induced
cardiomyopathy in untreated patients is unknown but is likely
to be small.
Although no randomized, double-blinded, placebo-
controlled clinical trials exist, beta blockers may be useful
and should be prescribed as first-line therapy in the majority
of these patients. Anecdotal evidence suggests that nondihy-
dropyridine calcium-channel blockers, such as verapamil and
diltiazem, are also effective.
Sinus node modification by catheter ablation remains a
potentially important therapeutic option in the most refractory
cases of inappropriate sinus tachycardia. Potential adverse
effects include pericarditis, phrenic nerve injury, superior
vena cava (SVC) syndrome, or need for permanent pacing. A
number of case reports have recorded successful surgical
excision or radiofrequency (RF) ablation of the sinus node
(44,45). The diagnosis of POTS (see Section V-A-3) must be
excluded before considering ablation. In a retrospective
analysis of 29 cases undergoing sinus node modification for
inappropriate sinus tachycardia (46), a 76% acute success rate
(22 out of 29 cases) was reported. The long-term success rate
has been reported to be around 66%. Table 2 lists recommen-
dations for treatment of inappropriate sinus tachycardia.
3. Postural Orthostatic Tachycardia Syndrome
This section of the full-text guideline has not been included in
the executive summary because it is not a disorder of the
sinus node. Please refer to Section V-A-3 of the full-text
guideline for differential diagnosis and treatment recommen-
dations on this topic.
4. Sinus Node Re-Entry Tachycardia
a. Definition
Sinus node re-entry tachycardias arise from re-entrant circuits
involving the sinus node’s production of paroxysmal, often
nonsustained bursts of tachycardia with P waves that are
similar, if not identical, to those in sinus rhythm. They are
usually triggered and terminated abruptly by an atrial prema-
ture beat.
b. Mechanism
Heterogeneity of conduction within the sinus node provides a
substrate for re-entry, but it is still not known whether the
re-entry circuit is isolated within the sinus node itself,
whether perisinus atrial tissue is necessary, or whether re-
entry around a portion of the crista terminalis is responsible.
The fact that this arrhythmia, like AVNRT, responds to vagal
maneuvers and adenosine, however, suggests that sinus node
tissue is involved in the re-entrant circuit.
c. Presentation
The incidence of sinus node re-entry tachycardia in patients
undergoing electrophysiological study for SVT ranges be-
tween 1.8% and 16.9% and up to 27% for those with focal
AT. Contrary to popular belief, there is a high incidence of
underlying organic heart disease in patients with sinus node
re-entry tachycardia. Patients present with symptoms of
palpitations, lightheadedness, and presyncope. Syncope is
extremely rare, as the rates of the tachycardia are rarely
higher than 180 bpm. An important clue for diagnosis is the
paroxysmal nature of the attacks.
d. Diagnosis
Sinus node re-entry tachycardia is diagnosed on the basis of
invasive and noninvasive criteria (43). Clinically, the follow-
ing features are highly suggestive of this arrhythmia:
1. The tachycardia and its associated symptoms are
paroxysmal.
2. P-wave morphology is identical to sinus rhythm with the
vector directed from superior to inferior and from right to
left.
3. Endocardial atrial activation is in a high-to-low and
right-to-left pattern, with an activation sequence similar to
that of sinus rhythm.
4. Induction and/or termination of the arrhythmia occurs with
premature atrial stimuli.
5. Termination occurs with vagal maneuvers or adenosine.
6. Induction of the arrhythmia is independent of atrial or
AV-nodal conduction time.
e. Treatment
There have been no controlled trials of drug prophylaxis
involving patients with sinus node re-entrant tachycardia.
Clinically suspected cases of symptomatic sinus node re-
entrant tachycardia may respond to vagal maneuvers, adeno-
TABLE 2. Recommendations for Treatment of Inappropriate Sinus Tachycardia
Treatment Recommendation Classification Level of Evidence References
Medical Beta blockers I C   
Verapamil, diltiazem IIa C   
Interventional Catheter ablation—sinus node
modification/elimination*
IIb C 44–51
The order in which treatment recommendations appear in this table within each class of
recommendation does not necessarily reflect a preferred sequence of administration. Please refer to
text for details. For pertinent drug dosing information please refer to the ACC/AHA/ESC Guidelines on
the Management of Patients With Atrial Fibrillation.
*Used as a last resort.
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sine, amiodarone, beta blockers, nondihydropyridine
calcium-channel blockers, or even digoxin. Patients whose
tachyarrhythmias are well tolerated and easily controlled by
vagal maneuvers and/or drug therapy should not be consid-
ered for electrophysiological studies. Electrophysiological
studies are indicated for patients with frequent or poorly
tolerated episodes of tachycardia that do not adequately
respond to drug therapy and for patients in whom the exact
nature of the tachycardia is uncertain and for whom electro-
physiological studies would aid appropriate therapy. Radio-
frequency catheter ablation of persistent sinus node re-entry
tachycardias identified through electrophysiological study is
generally successful (52).
B. Atrioventricular Nodal Reciprocating
Tachycardia
1. Definitions and Clinical Features
Atrioventricular nodal reciprocating tachycardia is the most
common form of PSVT. It is more prevalent in females; is
associated with palpitations, dizziness, and neck pulsations;
and is not usually associated with structural heart disease.
Rates of tachycardia are often between 140 and 250 per
minute.
Although the re-entrant circuit was initially thought to be
confined to the compact AV node, a more contemporary view
recognizes the usual participation of perinodal atrial tissue as
the most common component of the re-entrant circuit. It has
been shown convincingly, however, that AVNRT may persist
without participation of atrial tissue. Atrioventricular nodal
reciprocating tachycardia involves reciprocation between two
functionally and anatomically distinct pathways. In most
cases, the fast pathway appears to be located near the apex of
Koch’s triangle. The slow pathway extends inferoposterior to
the compact AV-node tissue and stretches along the septal
margin of the tricuspid annulus at the level of, or slightly
superior to, the coronary sinus.
During typical AVNRT, the fast pathway serves as the
retrograde limb of the circuit, whereas the slow pathway is
the anterograde limb (ie, slow–fast AV-node re-entry). After
conduction through the slow pathway to the His bundle and
ventricle, brisk conduction back to the atrium over the fast
pathway results in inscription of the shorter duration (40 ms)
P wave during or close to the QRS complex (less than or
equal to 70 ms) often with a pseudo-r in V1 (see Figure 3).
Less commonly (approximately 5% to 10%), the tachycardia
circuit is reversed such that conduction proceeds anterograde-
ly over the fast pathway and retrogradely over the slow
pathway (ie, fast–slow AV-node re-entry, or atypical
AVNRT) producing a long R-P tachycardia (ie, atypical
AVNRT) but other circuits may also be involved. The P
wave, negative in leads III and aVF, is inscribed prior to the
QRS. Infrequently, both limbs of the tachycardia circuit are
composed of slowly conducting tissue (ie, slow–slow AV-
node re-entry), and the P wave is inscribed after the QRS (ie,
RP interval more than or equal to 70 ms).
2. Acute Treatment
Acute evaluation and treatment of the patient with PSVT are
discussed in Sections IV-A and IV-B.
3. Long-Term Pharmacologic Therapy
For patients with frequent, recurrent sustained episodes of
AVNRT who prefer long-term oral therapy instead of cathe-
ter ablation, a spectrum of antiarrhythmic agents is available.
Standard therapy includes nondihydropyridine calcium-
channel blockers, beta blockers, and digoxin. In patients
without structural heart disease who do not respond to
AV-nodal–blocking agents, the class Ic drugs flecainide and
propafenone have become the preferred choice. In most
cases, class III drugs, such as sotalol or amiodarone, are
unnecessary (53). Class Ia drugs, such as quinidine, procain-
amide, and disopyramide, have limited appeal due to their
multidosing regimens, modest efficacy, and adverse and
proarrhythmic effects.
A major limitation in evaluating antiarrhythmic agents for
treating AVNRT is the general absence of large multicenter,
randomized, placebo-controlled studies.
a. Prophylactic Pharmacologic Therapy
(1) Calcium-Channel Blockers, Beta Blockers, and Digoxin.
Comments regarding the long-term efficacy of calcium-
channel blockers, beta blockers, and digoxin taken orally
for management of AVNRT are limited by the small
number of randomized patients studied. A small random-
ized (11 patients), double-blinded, placebo-controlled
trial showed that verapamil taken orally decreases the
number and duration of both patient-reported and elec-
trophysiologically-recorded episodes. A similar finding
was demonstrated with doses of 360 to 480 mg/d with a
trend toward greater effect with higher doses; however,
the study was underpowered to detect a modest
difference.
Oral digoxin (0.375 mg/d), verapamil (480 mg/d), and
propranolol (240 mg/d) showed similar efficacy in 11
patients in a randomized, double-blinded, crossover
study. There was no difference among the drugs with
respect to frequency or duration of PSVT.
(2) Class I Drugs. The data showing efficacy of procain-
amide, quinidine, and disopyramide are from the older
literature and are derived from small studies. These drugs
are rarely used for treating AVNRT today.
Long-term benefits of oral flecainide in AVNRT were
initially shown in an open-labeled study. At doses be-
tween 200 and 300 mg/d, flecainide completely sup-
pressed episodes in 65% of patients. Several double-
blinded, placebo-controlled trials have confirmed the
efficacy of flecainide for prevention of recurrences.
Events are reduced when compared with placebo, with an
increase in the median time to the first recurrence and a
greater interval between attacks. Open-labeled, long-term
studies suggest excellent chronic tolerance and safety. In
patients without structural heart disease, 7.6% discontin-
ued the drug due to a suboptimal clinical response, and
5% discontinued it because of noncardiac (usually central
nervous system) side effects. Class Ic agents (ie, flecain-
ide and propafenone) are contraindicated for patients
with structural heart disease. Moreover, class Ic drugs are
often combined with beta-blocking agents to enhance
efficacy and reduce the risk of one-to-one conduction
over the AV node if atrial flutter occurs.
Flecainide appears to have greater long-term efficacy
than verapamil. Although both drugs (median doses 200
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mg/d and 240 mg/d, respectively) have an equivalent
reduction in the frequency of episodes, 30% of patients
had complete suppression of all symptomatic episodes
with flecainide, whereas 13% had complete suppression
with verapamil. Discontinuation rates due to adverse
effects were equivalent, 19% and 24%, respectively.
Propafenone is also an effective drug for prophylaxis
of AVNRT. In a double-blinded, placebo-controlled trial,
in which time to treatment failure was analyzed, the RR
of treatment failure for placebo versus propafenone was
6.8. A single-center, randomized, double-blinded,
placebo-controlled study showed that propafenone (300
mg taken three times per day) reduced the recurrence rate
to one-fifth of that of placebo.
(3) Class III Drugs. Limited prospective data are available
for use of class III drugs (eg, amiodarone, sotalol,
dofetilide). Although many have been used effectively to
prevent recurrences, routine use should be avoided due to
their toxicities, including proarrhythmia (ie, torsades de
pointes). A placebo-controlled trial found sotalol to be
superior to placebo in prolonging time to recurrence of
PSVT. With regard to dofetilide, a multicenter, random-
ized, placebo-controlled study showed that patients with
PSVT had a 50% probability of complete symptomatic
suppression with dofetilide over a 6-month follow-up
(500 g taken twice per day), whereas the probability of
suppression in the control group was 6% (p less than
0.001). There were no proarrhythmic events (53). In this
study, dofetilide was shown to be as effective as
propafenone (150 mg taken three times per day).
Little data exists regarding the effects of amiodarone
on AVNRT. In one open-labeled study in the electro-
physiology laboratory, IV amiodarone (5 mg · kg1 · 5
minutes1) terminated tachycardia in seven out of nine
patients. Treatment with oral amiodarone (maintenance
dose 200 to 400 mg/d) for 66 plus or minus 24 days
prevented recurrence and inducibility in all patients, with
its predominant effect being the depression of conduction
in the retrograde fast pathway. Of note, amiodarone has
been shown to be safe in structural heart disease, partic-
ularly LV dysfunction.
b. Single-Dose Oral Therapy (Pill-in-the-Pocket)
Single-dose therapy refers to administration of a drug only
during an episode of tachycardia for the purpose of termina-
tion of the arrhythmia when vagal maneuvers alone are not
effective. This approach is appropriate to consider for patients
with infrequent episodes of AVNRT that are prolonged (ie,
lasting hours) but yet well tolerated (54), and obviates
exposure of patients to chronic and unnecessary therapy
between their rare arrhythmic events. This approach necessi-
tates the use of a drug that has a short time to take effect (ie,
immediate-release preparations). Candidate patients should
be free of significant LV dysfunction, sinus bradycardia, or
pre-excitation.
A single oral dose of flecainide (approximately 3 mg/kg)
has been reported to terminate acute episodes of AVNRT in
adolescents and young adults without structural heart disease,
although it offered no benefit compared with placebo in other
studies (54).
Single-dose oral therapy with diltiazem (120 mg) plus
propranolol (80 mg) has been shown to be superior to both
placebo and flecainide in sequential testing in 33 patients
with PSVT in terms of conversion to sinus rhythm (54).
Favorable results comparing diltiazem plus propranolol with
placebo have also been reported by others. Hypotension and
sinus bradycardia are rare complications. Single-dose therapy
with diltiazem plus propranolol is associated with a signifi-
cant reduction in emergency room visits in appropriately
selected patients (54).
4. Catheter Ablation
Targeting the slow pathway along the posteroseptal region of
the tricuspid annulus markedly reduces the risk of heart block
and is the preferable approach. A prospective, randomized
comparison of the fast- and slow-pathway approaches dem-
onstrates equivalent success rates. Advantages of slow-
pathway ablation include a lower incidence of complete AV
block (1% versus 8%) and the absence of the hemodynamic
consequences of marked prolongation of the PR interval.
Hence, slow pathway ablation is always used initially and fast
pathway ablation is considered only when slow pathway
ablation fails.
The NASPE Prospective Catheter Ablation Registry in-
cluded 1197 patients who underwent AV-nodal modification
for AVNRT. Success was achieved in 96.1%, and the only
significant complication was a 1% incidence of second-
degree or third-degree AV block (55). These data have been
confirmed by others (56). Atrioventricular block may com-
plicate slow-pathway ablation caused by posterior displace-
ment of the fast pathway, superior displacement of the slow
pathway (and coronary sinus), or inadvertent anterior dis-
placement of the catheter during RF application. Pre-existing
first-degree AV block does not appear to increase appreciably
the risk of developing complete AV block, although caution
is advised. The recurrence rate after ablation is approximately
3% to 7% (56,57).
Ablation of the slow pathway may be performed in patients
with documented SVT (which is morphologically consistent
with AVNRT) but in whom only dual AV-nodal physiology
(but not tachycardia) is demonstrated during electrophysio-
logical study. Because arrhythmia induction is not an avail-
able endpoint for successful ablation in this circumstance, the
surrogate endpoint of an accelerated junctional rhythm during
ablation is a good indication of slow-pathway ablation.
Slow-pathway ablation may be considered at the discretion
of the physician when sustained (more than 30 seconds)
AVNRT is induced incidentally during an ablation procedure
directed at a different clinical tachycardia.
Indications for ablation depend on clinical judgment and
patient preference. Factors that contribute to the therapeutic
decision include the frequency and duration of tachycardia,
tolerance of symptoms, effectiveness and tolerance of antiar-
rhythmic drugs, the need for lifelong drug therapy, and the
presence of concomitant structural heart disease. Catheter
ablation has become the preferred therapy, over long-term
pharmacologic therapy, for management of patients with
AVNRT. The decision to ablate or proceed with drug therapy
as initial therapy is, however, often patient specific, related to
lifestyle issues (eg, planned pregnancy, competitive athlete,
recreational pilot), affected by individual inclinations or
aversions with regard to an invasive procedure or the chro-
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nicity of drug therapy, and influenced by the availability of an
experienced center for ablation. Because drug efficacy is in
the range of 30% to 50%, catheter ablation may be offered as
first-line therapy for patients with frequent episodes of
tachycardia. Patients considering RF ablation must be willing
to accept the risk, albeit low, of AV block and pacemaker
implantation. Table 3 lists recommendations for long-term
treatment of patients with recurrent AVNRT.
C. Focal and Nonparoxysmal
Junctional Tachycardia
1. Focal Junctional Tachycardia
a. Definition
Abnormally rapid discharges from the junctional region have
been designated by a number of terms, each of which has
deficiencies. For example, some refer to these disorders as
“junctional ectopic tachycardia.” The problem with this term
is redundancy because all pacemakers outside of the sinus
node are, in fact, ectopic. The term “automatic junctional
tachycardia” suggests that the dominant mechanism is abnor-
mal automaticity; however, mechanisms other than abnormal
automaticity may be operative. The writing committee be-
lieves it is reasonable to designate these arrhythmias as focal
junctional tachycardia, which has a neutral connotation with
regard to arrhythmic mechanism.
b. Diagnoses
The unifying feature of focal junctional tachycardias is their
origin from the AV node or His bundle. This site of arrhythmia
origin results in varied ECG manifestations because the arrhyth-
mia requires participation of neither the atrium nor the ventricle
for its propagation. The ECG features of focal junctional
tachycardia include heart rates of 110 to 250 bpm and a narrow
complex or typical BBB conduction pattern. Atrioventricular
dissociation is often present (Figure 8), although one-to-one
retrograde conduction may be transiently observed. On occasion,
the junctional rhythm is quite erratic, suggesting AF. Finally,
isolated, concealed junctional extrasystoles that fail to conduct to
TABLE 3. Recommendations for Long-Term Treatment of Patients With Recurrent AVNRT
Clinical Presentation Recommendation Class Level of Evidence References
Poorly tolerated AVNRT with hemodynamic
intolerance
Catheter ablation I B 58
Verapamil, diltiazem, beta blockers, sotalol,
amiodarone
IIa C 58
Flecainide,* propafenone* IIa C
Recurrent symptomatic AVNRT Catheter ablation I B 58
Verapamil I B 59
Diltiazem, beta blockers I C 60
Digoxin† IIb C
Recurrent AVNRT unresponsive to beta
blockade or calcium-channel blocker and
patient not desiring RF ablation
Flecainide,* propafenone,* sotalol IIa B 53,61–65
Amiodarone IIb C 66
AVNRT with infrequent or single episode in
patients who desire complete control of
arrhythmia
Catheter ablation I B
Documented PSVT with only dual AV-nodal
pathways or single echo beats demonstrated
during electrophysiological study and no
other identified cause of arrhythmia
Verapamil, diltiazem, beta blockers, flecainide,*
propafenone*
I C
Catheter ablation‡ I B
Infrequent, well-tolerated AVNRT No therapy I C 58
Vagal maneuvers I B
Pill-in-the-pocket I B
Verapamil, diltiazem, beta blockers I B
Catheter ablation I B 67
The order in which treatment recommendations appear in this table within each class of recommendation does not necessarily reflect a preferred
sequence of administration. Please refer to text for details. For pertinent drug dosing information please refer to the ACC/AHA/ESC Guidelines on the
Management of Patients With Atrial Fibrillation.
*Relatively contraindicated for patients with coronary artery disease, LV dysfunction, or other significant heart disease.
†Digoxin is often ineffective because its pharmacologic effects can be overridden by enhanced sympathetic tone.
‡Decision depends on symptoms.
AV indicates atrioventricular; AVNRT, atrioventricular nodal reciprocating tachycardia; LV, left ventricular; PSVT, paroxysmal supraventricular
tachycardia; RF, radiofrequency.
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the ventricles may produce episodic AV block by rendering the
AV node intermittently refractory.
During electrophysiological study, each ventricular depo-
larization is preceded by a His bundle deflection (68). The
precise electrophysiological mechanism of this arrhythmia is
thought to be either abnormal automaticity or triggered
activity based on its response to beta-adrenergic stimulation
and calcium-channel blockade.
c. Clinical Features
Focal junctional tachycardia, also known as automatic or
paroxysmal junctional tachycardia, is a very uncommon
arrhythmia. It is rare in the pediatric population and even less
common in adults. Under the common umbrella of “focal
junctional tachycardia” are several distinct clinical syn-
dromes. The most prevalent among these, so-called “congen-
ital junctional ectopic tachycardia” and “postoperative junc-
tional ectopic tachycardia,” occur exclusively in pediatric
patients and are, therefore, outside of the scope of this
document.
Focal junctional tachycardia usually presents in young
adulthood. It has been speculated that this form of arrhythmia
is an adult extension of the pediatric disorder commonly
termed “congenital junctional ectopic tachycardia.” If this is
the case, then it appears to be more benign than is the
pediatric form. This arrhythmia is usually exercise or stress
related and may be found in patients with structurally normal
hearts or in patients with congenital abnormalities, such as
atrial or ventricular septal defects. The patients are often quite
symptomatic and, if untreated, may develop heart failure,
particularly if their tachycardia is incessant.
d. Management
Relatively little information is available about the response of
rapid focal junctional tachycardia to suppressive drug ther-
apy. Patients typically show some responsiveness to beta
blockade. The tachycardia can be slowed or terminated with
IV flecainide and shows some positive response to long-term
oral therapy. Drug therapy is only variably successful, and
ablative techniques have been introduced to cure tachycardia.
Catheter ablation can be curative by destroying foci adjacent
to the AV node but the procedure appears to be associated
with risk (5% to 10%) of AV block.
In one series, 17 patients with focal junctional tachycardia
were referred for electrophysiological testing and possible
catheter ablation. Ten of 11 patients undergoing RF catheter
ablation in this series had acute tachycardia elimination. Eight
patients remained symptom free during follow-up (68).
2. Nonparoxysmal Junctional Tachycardia
a. Definition and Clinical Features
Nonparoxysmal junctional tachycardia is a benign arrhythmia
that is characterized by a narrow complex tachycardia with
rates of 70 to 120 bpm. The arrhythmia mechanism is thought
to be enhanced automaticity arising from a high junctional
focus (14) or in response to a triggered mechanism. It shows
a typical “warm-up” and “cool-down” pattern and cannot be
terminated by pacing maneuvers. The most important feature
about this tachycardia is that it may be a marker for a serious
underlying condition, such as digitalis toxicity, postcardiac
surgery, hypokalemia, or myocardial ischemia. Other associ-
ated conditions include chronic obstructive lung disease with
hypoxia, and inflammatory myocarditis. Unlike the more
rapid form of focal junctional tachycardia, there is commonly
one-to-one AV association. In some cases, particularly in the
setting of digitalis toxicity, anterograde AV-nodal Wenck-
ebach conduction block may be observed.
The diagnosis must be differentiated from other types of
narrow complex tachycardia, including AT, AVNRT, and
AVRT. Usually, the clinical setting in which the arrhythmia
presents and the ECG findings allow the clinician to ascertain
the arrhythmia mechanism. In some cases, however, the
mechanism may be determined only with invasive electro-
physiological testing.
b. Management
The mainstay of managing nonparoxysmal junctional
tachycardia is to correct the underlying abnormality. With-
holding digitalis when junctional tachycardia is the only
clinical manifestation of toxicity is usually adequate.If, how-
ever, ventricular arrhythmias or high-grade heart block are
observed, then treatment with digitalis-binding agents may be
indicated. It is not unusual for automatic activity from the AV
node to exceed the sinus rate, leading to loss of AV
synchrony. This should be regarded as a physiological con-
dition, and no specific therapy is indicated. Persisting junc-
tional tachycardia may be suppressed by beta blockers or
calcium-channel blockers (14). In rare cases, the emergence
of a junctional rhythm is the result of sinus node dysfunction.
Sympathetic stimulation of the AV-junction automaticity can
lead to an AV-junctional rhythm that supersedes the sinus
rhythm. In these cases, symptoms mimicking “pacemaker
syndrome” may occur due to retrograde conduction from the
AV junction to the atrium and resultant atrial contraction
against closed atrioventricular valves, resulting in cannon A
waves and possible hypotension. Atrial pacing is an effective
treatment for this condition. Table 4 lists recommendations
for treatment of focal and nonparoxysmal junctional
tachycardia syndromes.
Figure 8. Surface ECG recording from leads V1, II, and V5 in a
patient with focal junctional tachycardia. The upper panel shows
sinus rhythm. The lower panel shows tachycardia onset with the
characteristic finding of isorhythmic AV dissociation (arrows).
The large arrow signifies continuous recording. AV indicates
atrioventricular.
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D. Atrioventricular Reciprocating Tachycardia
(Extra Nodal Accessory Pathways)
Typical accessory pathways are extra nodal pathways that
connect the myocardium of the atrium and the ventricle
across the AV groove. Delta waves detectable on an ECG
have been reported to be present in 0.15% to 0.25% of the
general population. Pathway conduction may be intermittent.
A higher prevalence of 0.55% has been reported in first-
degree relatives of patients with accessory pathways. Acces-
sory pathways can be classified on the basis of their location
along the mitral or tricuspid annulus; type of conduction
(decremental [ie, progressive delay in accessory pathway
conduction in response to increased paced rates] or nondec-
remental); and whether they are capable of anterograde
conduction, retrograde conduction, or both. Accessory path-
ways usually exhibit rapid, nondecremental conduction, sim-
ilar to that present in normal His-Purkinje tissue and atrial or
ventricular myocardium. Approximately 8% of accessory
pathways display decremental anterograde or retrograde con-
duction. The term “permanent form of junctional reciprocat-
ing tachycardia” is used to refer to a rare clinical syndrome
involving a slowly conducting, concealed, usually postero-
septal (inferoseptal) accessory pathway. This syndrome is
characterized by an incessant SVT, usually with negative P
waves in leads II, III, and aVF and a long RP interval (RP
more than PR).
Accessory pathways that are capable of only retrograde
conduction are referred to as “concealed,” whereas those
capable of anterograde conduction are “manifest,” demon-
strating pre-excitation on a standard ECG. The degree of
pre-excitation is determined by the relative conduction to the
ventricle over the AV node His bundle axis versus the
accessory pathway. In some patients, anterograde conduction
is apparent only with pacing close to the atrial insertion site,
as, for example, for left-lateral–located pathways. Manifest
accessory pathways usually conduct in both anterograde and
retrograde directions. Those that conduct in the anterograde
direction only are uncommon, whereas those that conduct in
the retrograde direction are common.
The diagnosis of WPW syndrome is reserved for patients
who have both pre-excitation and tachyarrhythmias. Among
patients with WPW syndrome, AVRT is the most common
arrhythmia, accounting for 95% of re-entrant tachycardias
that occur in patients with an accessory pathway.
Atrioventricular re-entry tachycardia is further subclassi-
fied into orthodromic and antidromic AVRT. During ortho-
dromic AVRT, the re-entrant impulse conducts over the AV
node and the specialized conduction system from the atrium
to the ventricle and utilizes the accessory pathway for
conduction from the ventricle to the atrium. During anti-
dromic AVRT, the re-entrant impulse travels in the reverse
direction, with anterograde conduction from the atrium to the
ventricle occurring via the accessory pathway and retrograde
conduction over the AV node or a second accessory pathway.
Antidromic AVRT occurs in only 5% to 10% of patients with
WPW syndrome. Pre-excited tachycardias can also occur in
patients with AT, atrial flutter, AF, or AVNRT, with the
accessory pathway acting as a bystander (ie, not a critical part
of the tachycardia circuit).
Atrial fibrillation is a potentially life-threatening arrhyth-
mia in patients with WPW syndrome. If an accessory path-
way has a short anterograde refractory period, then rapid
repetitive conduction to the ventricles during AF can result in
a rapid ventricular response with subsequent degeneration to
VF. It has been estimated that one-third of patients with
WPW syndrome also have AF. Accessory pathways appear to
play a pathophysiological role in the development of AF in
these patients, as most are young and do not have structural
heart disease. Rapid AVRT may play a role in initiating AF
in these patients. Surgical or catheter ablation of accessory
pathways usually eliminates AF as well as AVRT (81).
1. Sudden Death in WPW Syndrome and Risk
Stratification
The incidence of sudden cardiac death in patients with the
WPW syndrome has been estimated to range from 0.15% to
0.39% over 3- to 10-year follow-up. It is unusual for cardiac
arrest to be the first symptomatic manifestation of WPW
syndrome. Conversely, in about half of the cardiac arrest
TABLE 4. Recommendations for Treatment of Focal and Nonparoxysmal Junctional Tachycardia Syndromes
Tachycardia Recommendation Classification Level of Evidence References
Focal junctional tachycardia Beta blockers IIa C
Flecainide IIa C 69
Propafenone* IIa C 70
Sotalol* IIa C 71
Amiodarone* IIa C 72,73
Catheter ablation IIa C 68,74–76
Nonparoxysmal junctional tachycardia Reverse digitalis toxicity I C 77,78
Correct hypokalemia I C
Treat myocardial ischemia I C 79
Beta blockers, calcium-channel blockers IIa C 14,80
The order in which treatment recommendations appear in this table within each class of recommendation does not necessarily reflect a preferred
sequence of administration. Please refer to text for details. For pertinent drug dosing information please refer to the ACC/AHA/ESC Guidelines on the
Management of Patients With Atrial Fibrillation.
*Data available for pediatric patients only.
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cases in WPW patients, it is the first manifestation of WPW.
Given the potential for AF among patients with WPW
syndrome and the concern about sudden cardiac death result-
ing from rapid pre-excited AF, even the low annual incidence
of sudden death among patients with the WPW syndrome is
of note and supports the concept of liberal indications for
catheter ablation.
Studies of WPW syndrome patients who have experienced
a cardiac arrest have retrospectively identified a number of
markers that identify patients at increased risk. These include
1) a shortest pre-excited R-R interval less than 250 ms during
spontaneous or induced AF, 2) a history of symptomatic
tachycardia, 3) multiple accessory pathways, and 4) Ebstein’s
anomaly. A high incidence of sudden death has been reported
in familial WPW. This familial presentation is, however,
exceedingly rare (82). Several noninvasive and invasive tests
have been proposed as useful in risk-stratifying patients for
sudden death risk. The detection of intermittent pre-
excitation, which is characterized by an abrupt loss of the
delta wave and normalization of the QRS complex, is
evidence that an accessory pathway has a relatively long
refractory period and is unlikely to precipitate VF. The loss of
pre-excitation after administration of the antiarrhythmic drug
procainamide has also been used to indicate a low-risk
subgroup. Noninvasive tests are considered inferior to inva-
sive electrophysiological assessment for risk of sudden car-
diac death. For this reason, noninvasive tests currently play
little role in patient management.
2. Acute Treatment
The approach to acute evaluation and management during a
sustained regular tachycardia is covered in Sections IV. A and
IV. B. The approach to acute termination of these arrhythmias
generally differs from that used for long-term suppression
and prevention of further episodes of SVT.
a. Special Considerations for Patients With Wide-Complex
(Pre-Excited) Tachycardias
In patients with antidromic tachycardia, drug treatment may
be directed at the accessory pathway or at the AV node
because both are critical components of the tachycardia
circuit. Atrioventricular nodal–blocking drugs would, how-
ever, be ineffective in patients who have anterograde conduc-
tion over one pathway and retrograde conduction over a
separate accessory pathway because the AV node is not
involved in the circuit. Adenosine should be used with
caution because it may produce AF with a rapid ventricular
rate in pre-excited tachycardias. Ibutilide, procainamide, or
flecainide, which are capable of slowing the conduction
through the pathway, are preferred.
Pre-excited tachycardias occurring in patients with either
AT or atrial flutter with a bystander accessory pathway may
present with a one-to-one conduction over the pathway.
Caution is advised against AV-nodal–blocking agents, which
would obviously be ineffective in this situation. Antiarrhyth-
mic drugs, which prevent rapid conduction through the
bystander pathway, are preferable, even if they may not
convert the atrial arrhythmia. Similarly, it is preferable to
treat pre-excited AF by either IV ibutilide, flecainide, or
procainamide.
3. Long-Term Pharmacologic Therapy
Antiarrhythmic drugs represent one therapeutic option for
management of accessory pathway–mediated arrhythmias,
but they have been increasingly replaced by catheter ablation.
Antiarrhythmic drugs that primarily modify conduction
through the AV node include digoxin, verapamil, beta block-
ers, adenosine, and diltiazem. Antiarrhythmic drugs that
depress conduction across the accessory pathway include
class I drugs, such as procainamide, disopyramide,
propafenone, and flecainide, as well as class III antiarrhyth-
mic drugs, such as ibutilide, sotalol, and amiodarone.
a. Prophylactic Pharmacologic Therapy
There have been no controlled trials of drug prophylaxis
involving patients with AVRT; however, a number of small,
nonrandomized trials have been performed (each involving
less than 50 patients), and they have reported the safety and
efficacy of drug therapy for maintenance of sinus rhythm in
patients with supraventricular arrhythmias. A subset of the
patients in these studies had AVRT as their underlying
arrhythmia. Available data do not allow a comparison of the
efficacy of these drugs relative to one another. The drugs
available to treat AVRT include any drug that alters either
conduction through the AV node (eg, nondihydropyridine
calcium-channel blockers, beta blockers, digoxin) or a drug
that alters conduction through the atrium, ventricle, or acces-
sory pathway (eg, class Ia, Ic, or III antiarrhythmic agents).
The available data are outlined below. Of note is that no
studies have examined the efficacy of chronic oral beta
blockers in the treatment of AVRT and/or WPW syndrome.
The absence of studies specifically examining the role of
beta-blocker therapy in the treatment of WPW syndrome
likely reflects the fact that catheter ablation is the therapy of
choice for these patients. Despite the absence of data from
clinical trials, chronic oral beta-blocker therapy may be used
for treatment of patients with WPW syndrome, particularly if
their accessory pathway has been demonstrated during elec-
trophysiological testing to be incapable of rapid anterograde
conduction.
(1) Propafenone. The largest published study that reported
the efficacy of propafenone in adult patients involved 11
individuals. Propafenone resulted in anterograde conduc-
tion block in the accessory pathway in 4 of 9 patients and
retrograde block in 3 of 11 patients. Atrioventricular
re-entry tachycardia was rendered noninducible in 6 of 11
patients. During 9 plus or minus 6 months of follow-up,
none of the 10 patients discharged on a combination of
propafenone and a beta blocker experienced a recurrence.
No major side effects were reported. Other small trials
have evaluated the efficacy of propafenone in the treat-
ment of AVRT in children. The largest of these involved
41 children. Chronic administration of propafenone was
effective in 69%. Side effects occurred in 25% of these
patients.
(2) Flecainide. A number of studies have examined the acute
and long-term efficacy of oral and IV flecainide in the
treatment of patients with AVRT. The largest of these
studies involved 20 patients with AVRT. The oral ad-
ministration of flecainide (200 to 300 mg/d) resulted in
an inability to induce sustained tachycardia in 17 of the
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20 patients. The electrophysiological effects of flecainide
were partially reversed by administration of isoprotere-
nol. During 15 plus or minus 7 months of follow-up on
oral flecainide treatment, 3 patients developed a recur-
rence of tachycardia. Other studies have reported similar
findings. The addition of a beta blocker results in greater
efficacy, with more than 90% of patients achieving
abolition of symptomatic tachycardia. In addition to
studies that specifically focused on patients with a known
AVRT, several randomized trials have evaluated the
efficacy of flecainide in the treatment of patients with
PSVT of undetermined tachycardia mechanism. One
study enrolled 34 patients with PSVT into a double-
blinded, placebo-controlled trial with an 8-week cross-
over trial design. Flecainide was shown to be superior to
placebo; 8 of the 34 patients had a recurrence during
flecainide therapy, as compared with 29 of 34 patients
having a recurrence on placebo. Treatment with flecain-
ide also increases the time to first symptomatic event and
time to subsequent events.
(3) Sotalol. The efficacy of oral sotalol in the prevention of
AVRT has been reported in a single study, which
involved 17 patients with an accessory pathway. Fourteen
of 15 patients with inducible sustained tachycardia during
electrophysiological testing continued to have inducible
tachycardia after administration of IV sotalol. Thirteen of
the 16 patients who were discharged taking oral sotalol
were free of symptomatic recurrences during a median of
36 months of follow-up.
(4) Amiodarone. Several studies have evaluated the efficacy
of amiodarone in the treatment of patients with accessory
pathway–mediated tachycardias. These studies, however,
do not demonstrate that amiodarone is superior to class Ic
antiarrhythmic agents or sotalol. As a result of these
findings, combined with the well-recognized organ tox-
icity associated with amiodarone and the high rate of
discontinuation of this drug, amiodarone generally is not
warranted for treatment of patients with accessory path-
ways. Exceptions are for patients with structural heart
disease who are not thought to be candidates for catheter
ablation.
(5) Verapamil. The efficacy of verapamil in the prevention of
AVRT has been reported in a single study, which
involved seven patients. Four of these 17 patients con-
tinued to have inducible AVRT during electrophysiolog-
ical testing despite treatment with oral verapamil. Ade-
quate follow-up data in these patients were not provided
in this manuscript. Intravenous verapamil can precipitate
hemodynamic deterioration during AF. Verapamil and
diltiazem should not be used as the sole therapy for
patients with accessory pathways that might be capable
of rapid conduction during AF. This concern also applies
to digoxin, which also should not be used in this
situation.
(6) Other Drugs. No studies have been performed to deter-
mine the short- or long-term efficacy of procainamide or
quinidine in the treatment of AVRT.
b. Single-Dose Oral Therapy (Pill-in-the-Pocket)
Some patients with infrequent episodes of tachycardia may be
managed with the single-dose “pill-in-the-pocket” approach:
taking an antiarrhythmic drug only at the onset of a
tachycardia episode (54). This approach to treatment is
reserved for patients without pre-excitation and with infre-
quent and hemodynamically tolerated tachycardia. A recent
study reported that 94% of induced PSVT episodes were
terminated in the electrophysiology laboratory within 32
minutes plus or minus 22 minutes by administration of a
combination of diltiazem (120 mg) plus propranolol (80 mg).
This treatment was successful in terminating PSVT within 2
hours during outpatient follow-up in 81% of patients. Another
finding of this study was that flecainide, when given as a
single dose for acute termination of PSVT, was significantly
less effective than the combination of diltiazem and
propranolol.
4. Catheter Ablation
Catheter ablation of accessory pathways is performed in
conjunction with a diagnostic electrophysiological test. The
purposes of the electrophysiological test are to confirm the
presence of an accessory pathway, determine its conduction
characteristics, and define its role in the patient’s clinical
arrhythmia. Once the arrhythmia is localized, ablation is
performed using a steerable ablation catheter. There have
been no prospective, randomized clinical trials that have
evaluated the safety and efficacy of catheter ablation of
accessory pathways; however, the results of catheter ablation
of accessory pathways have been reported in a large number
of single-center trials, one multicenter trial (57), and several
prospective registries (55). The initial efficacy of catheter
ablation of accessory pathways is approximately 95% in most
series (57). The success rate for catheter ablation of left
free-wall accessory pathways is slightly higher than for
catheter ablation of accessory pathways in other locations.
After an initially successful procedure, resolution of the
inflammation or edema associated with the initial injury
allows recurrence of accessory pathway conduction in ap-
proximately 5% of patients. Accessory pathways that recur
can usually be successfully ablated during a second session.
Complications associated with catheter ablation of acces-
sory pathways result from radiation exposure, vascular access
(eg, hematomas, deep venous thrombosis, arterial perforation,
arteriovenous fistula, pneumothorax), catheter manipulation
(eg, valvular damage, microemboli, perforation of the coro-
nary sinus or myocardial wall, coronary artery dissection,
thrombosis), or delivery of RF energy (eg, AV block, myo-
cardial perforation, coronary artery spasm or occlusion,
transient ischemic attacks, or cerebrovascular accidents)
(55,57). The procedure-related mortality reported for catheter
ablation of accessory pathways ranges from 0% to 0.2%
(55,57). The voluntary Multicenter European Radiofrequency
Survey (MERFS) reported data from 2222 patients who
underwent catheter ablation of an accessory pathway. The
overall complication rate was 4.4%, including 3 deaths
(0.13%). The 1995 NASPE survey of 5427 patients who
underwent catheter ablations of an accessory pathway re-
ported a total of 99 (1.82%) significant complications, includ-
ing 4 procedure-related deaths (0.08%). Among the 500
patients who underwent catheter ablation of an accessory
pathway as part of a prospective, multicenter clinical trial,
there was 1 death (0.2%). This patient died of dissection of
the left main coronary artery during an attempt at catheter
ablation of a left free-wall accessory pathway (57). The most
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common major complications are complete AV block and
cardiac tamponade. The incidence of inadvertent complete
AV block ranges from 0.17% to 1.0%. Most occur in the
setting of attempted ablation of septal accessory pathways
located close to the AV junction. The frequency of cardiac
tamponade varies between 0.13% and 1.1%.
5. Management of Patients With Asymptomatic
Accessory Pathways
An ECG pattern of pre-excitation is occasionally encountered
in a subject who has no symptoms of arrhythmia. The role of
electrophysiological testing and catheter ablation in asymp-
tomatic patients with pre-excitation is controversial. One-
third of asymptomatic individuals younger than 40 years of
age when pre-excitation was identified eventually developed
symptoms, whereas no patients in whom pre-excitation was
first uncovered after the age of 40 years developed symptoms.
Most patients with asymptomatic pre-excitation have a good
prognosis; cardiac arrest is rarely the first manifestation of the
disease. Prior studies have reported that approximately 20%
of asymptomatic patients will demonstrate a rapid ventricular
rate during AF induced during electrophysiological testing.
During follow-up, however, very few patients developed
symptomatic arrhythmias, and none of these individuals
experienced a cardiac arrest. The positive predictive value of
invasive electrophysiological testing is considered to be too
low to justify routine use in asymptomatic patients (83). The
decision to ablate pathways in individuals with high-risk
occupations, such as school bus drivers, pilots, and scuba
divers (83), is made on the basis of individual clinical
considerations. These recommendations are likely to remain
unchanged despite the results of a study that identified the
results of electrophysiological testing as an important predic-
tor of arrhythmic events in patients with asymptomatic
pre-excitation (84). This study reported the follow-up of 212
patients with asymptomatic pre-excitation, all of whom un-
derwent a baseline electrophysiological study. After 38 plus
or minus 16 months of follow-up, 33 patients became
symptomatic, and 3 of these patients experienced VF (result-
ing in death in 1 patient). The most important factor in
predicting outcome was the inducibility of AVRT or AF
during the baseline electrophysiological study. The presence
of multiple accessory pathways was also identified as a
predictor of future arrhythmic events. Of the 115 noninduc-
ible patients, only 3.4% developed a symptomatic supraven-
tricular arrhythmia during follow-up. In contrast, 62% of the
47 inducible patients developed a symptomatic arrhythmia
during follow-up (including the 3 patients who experienced
VF).
Patients with asymptomatic pre-excitation should be en-
couraged to seek medical expertise whenever arrhythmia-
related symptoms occur. The potential value of electrophys-
iological testing in identifying high-risk patients who may
benefit from catheter ablation must be balanced against the
approximately 2% risk of a major complication associated
with catheter ablation.
6. Summary of Management
In general, patients who have WPW syndrome (ie, pre-
excitation and symptoms), and particularly those with hemo-
dynamic instability during their arrhythmia, should undergo
catheter ablation as first-line therapy. Patients who experi-
ence infrequent minimally symptomatic episodes of SVT
who do not have evidence of pre-excitation can be treated
with a variety of approaches. These patients with concealed
accessory pathways can be managed as patients with
AVNRT. Patient preference is always an important consid-
eration. Catheter ablation has sufficient efficacy and low risk
to be used for symptomatic patients, either as initial therapy
or for patients experiencing side effects or arrhythmia recur-
rence during drug therapy. Table 5 lists recommendations for
long-term therapy of accessory pathway–mediated
arrhythmias.
E. Focal Atrial Tachycardias
1. Definition and Clinical Presentation
Focal ATs are characterized by regular atrial activation from
atrial areas with centrifugal spread (113). Focal ATs are
usually manifest by atrial rates between 100 and 250 bpm and
rarely at 300 bpm. Neither the sinus nor the AV node plays a
role in the initiation or perpetuation of the tachycardia.
Nonsustained AT is frequently found on Holter recordings
and seldom associated with symptoms. Sustained focal ATs
are relatively rare; they are diagnosed in about 10 to 15% of
patients referred for catheter ablation of SVT (114). The
prevalence of focal AT has been calculated to be 0.34% in
asymptomatic patients versus 0.46% in symptomatic patients
(115).
The outlook of patients with focal AT is usually benign
with the exception of incessant forms, which may lead to
tachycardia-induced cardiomyopathy (116). In adults, focal
AT can occur in the absence of cardiac disease, but it is often
associated with underlying cardiac abnormalities (114). Atrial
tachycardia, usually with AV block, may be produced by
digitalis excess. This arrhythmia may be exacerbated by
hypokalemia. Focal ATs may present as either paroxysmal or
permanent tachycardias.
2. Diagnosis
In ATs, the P waves generally occur in the second half of the
tachycardia cycle (see Section IV-B).Therefore, in ATs, the P
wave is frequently obscured by the T wave of the preceding
QRS complex (Figure 9). The PR interval is directly influ-
enced by the tachycardia rate. The presence of AV block
during tachycardia excludes AVRT and makes AVNRT very
unlikely. During ATs, an isoelectric baseline is usually
present between P waves, and it is used to distinguish AT
from typical or atypical flutter (ie, saw-toothed or sinusoidal
P-wave morphologies) (Figures 10 and 11). In the presence of
rapid rates and/or atrial conduction disturbances, however, P
waves can be very wide without an isoelectric baseline, thus
mimicking atrial flutter (113). It should also be emphasized
that an ECG pattern of AT with discrete P waves and
isoelectric baselines does not rule out macro–re-entrant
tachycardia, especially if complex structural heart disease is
present and/or there has been surgery for congenital heart
disease. The diagnosis of AT can be established with cer-
tainty only by an electrophysiological study, including map-
ping and entrainment.
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Although definite localization of the source of AT requires
intracardiac mapping, the P-wave morphology on the 12-lead
surface ECG is different from sinus rhythm and may be useful
for the determination of the site of origin of the focal AT. A
negative P wave in lead I or aVL, or a positive P wave in lead
V1, favors a left atrial origin. In addition, negative P waves in
the inferior leads are suggestive of a caudal origin, whereas a
positive P wave in those leads suggests a cranial origin. Of
interest, the P waves during sinus rhythm may be similar to
those originating from the high crista terminalis or right
superior pulmonary vein (117). The latter site will, however,
often show a positive P wave in lead V1; hence, a change in
P-wave polarity from sinus rhythm should arouse suspicion
of a right superior pulmonary vein (PV) site. Multilead body
surface potential mapping can be used to help localize the
tachycardia site of origin (118).
3. Site of Origin and Mechanisms
Focal ATs are not randomly distributed but rather tend to
cluster over certain anatomical zones. The majority of right-
sided ATs originate along the crista terminalis from the
sinoatrial node to the AV node (119,120). In the left atrium,
foci are often found in the pulmonary veins, in the atrial
septum, or on the mitral annulus (121); in many cases, they
are generators for AF.
Focal ATs are characterized by radial spread of activation
from a focus, with endocardial activation not extending
through the entire atrial cycle. The mechanism of focal
discharge is difficult to ascertain by clinical methods. Avail-
able information suggests that focal activity can be caused by
abnormal or enhanced automaticity, triggered activity (due to
delayed afterdepolarization), or micro–re-entry. The progres-
sive increase in atrial rate with tachycardia onset (ie, “warm-
up”) and/or progressive decrease before tachycardia termina-
tion (ie, “cool-down”) are suggestive of an automatic
mechanism. Automatic ATs tend to be incessant, especially
in children, whereas those attributed to triggered activity may
be either incessant or paroxysmal.
a. Drug-Induced Atrial Tachycardia
The drug most commonly associated with induction of focal
AT is digitalis. This drug-induced AT is usually characterized
by development of AT with AV block; hence, the ventricular
rate is not excessively rapid. Serum digoxin levels are helpful
for diagnoses. Treatment consists of discontinuing the digi-
talis. In cases of persistent advanced AV block, digitalis-
binding agents may be considered.
4. Treatment
The efficacy of antiarrhythmic drugs is poorly defined be-
cause the clinical definition of focal ATs is often not very
TABLE 5. Recommendations for Long-Term Therapy of Accessory Pathway–Mediated Arrhythmias
Arrhythmia Recommendation Classification Level of Evidence References
WPW syndrome (pre-excitation and
symptomatic arrhythmias), well tolerated
Catheter ablation I B 55,85–87
Flecainide, propafenone IIa C 64,86,88–99
Sotalol, amiodarone, beta blockers IIa C 100–104
Verapamil, diltiazem, digoxin III C 105
WPW syndrome (with AF and rapid-conduction
or poorly tolerated AVRT)
Catheter ablation I B 55,57,85,106–111
AVRT, poorly tolerated (no pre-excitation) Catheter ablation I B 55,57,85,106–111
Flecainide, propafenone IIa C 64,86,88–99
Sotalol, amiodarone IIa C 100–104
Beta blockers IIb C 105
Verapamil, diltiazem, digoxin III C 105
Single or infrequent AVRT episode(s) (no
pre-excitation)
None I C
Vagal maneuvers I B
Pill-in-the-pocket— verapamil,
diltiazem, beta blockers
I B 54,112
Catheter ablation IIa B 55,57,85,106–111
Sotalol, amiodarone IIb B 100–104
Flecainide, propafenone IIb C 64,86,88–99,105
Digoxin III C
Pre-excitation, asymptomatic None I C
Catheter ablation IIa B 55,57,85,106–111
The order in which treatment recommendations appear in this table within each class of recommendation does not necessarily reflect a preferred
sequence of administration. Please refer to text for details. For pertinent drug dosing information please refer to the ACC/AHA/ESC Guidelines on the
Management of Patients With Atrial Fibrillation.
AF indicates atrial fibrillation; AVRT, atrioventricular reciprocating tachycardia; WPW, Wolff-Parkinson-White.
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rigorous. No large studies have been conducted to assess the
effect of pharmacologic treatment on patients with focal ATs,
but both paroxysmal and incessant ATs are reported to be
difficult to treat medically.
a. Acute Treatment
On rare occasions, ATs may be terminated with vagal
maneuvers. A significant proportion of ATs will terminate
with administration of adenosine. Adenosine-sensitive
ATs are usually focal in origin (122,123). Persistence of
the tachycardia with AV block is also a common response
to adenosine. In addition, ATs that are responsive to IV
verapamil or beta blockers have been reported. It is
conceivable that the mechanism of AT in these patients
relates either to micro–re-entry, involving tissue with slow
conduction, or to triggered activity. Class Ia or class Ic
drugs may suppress automaticity or prolong action-
potential duration and, hence, may be effective for some
patients with AT.
For patients with automatic AT, atrial pacing (or adeno-
sine) may result in transient postpacing slowing but no
tachycardia termination. Similarly, DC cardioversion seldom
terminates automatic ATs, but DC cardioversion may be
successful for those in whom the tachycardia mechanism is
Figure 9. Focal atrial tachycardia showing a long RP interval relationship. The P wave in AT usually occurs in the latter part of the
tachycardia cycle (arrows) but can appear earlier, depending on the rate and status of AV-nodal conduction. AT indicates atrial
tachycardia; AV, atrioventricular.
Figure 10. 12-Lead ECG from a patient with counterclockwise
cavotricuspid isthmus–dependent flutter. Note that the flutter
waves in the inferior leads are predominantly negative (arrow),
whereas the flutter waves in lead V1 are positive (arrow). ms
indicates milliseconds.
Figure 11. 12-Lead ECG from a patient with clockwise cavotri-
cuspid isthmus–dependent flutter. Note that the flutter waves
are positive in the inferior leads and predominantly negative
double waves in lead V1. ms indicates milliseconds.
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micro–re-entry or triggered automaticity. An attempt at DC
cardioversion should, therefore, be considered for patients
with drug-resistant arrhythmia.
The usual acute therapy for AT consists of IV beta blockers
or calcium-channel blockers for either termination, which is
rare, or to achieve rate control through AV block, which is
often difficult to achieve. Direct suppression of the
tachycardia focus may be achieved by use of IV class Ia and
Ic or class III (eg, sotalol, amiodarone) agents. Intravenous
class Ia or Ic agents may be taken by patients without cardiac
failure, whereas IV amiodarone is preferred for those with
poor ventricular function (116).
b. Long-Term Pharmacologic Therapy
The available studies pertaining to long-term pharmaco-
logic therapy are observational, and there are problems in
discerning whether the tachycardias were carefully differen-
tiated from other mechanisms (ie, AVRT or AVNRT) or from
other forms of ATs. Review of the available data supports a
recommendation for initial therapy with calcium-channel
blockers or beta blockers because these agents may prove to
be effective and have minimal side effects. If these drugs are
unsuccessful, then class Ia, class Ic (flecainide and
propafenone) in combination with an AV-nodal–blocking
agent, or class III agents (sotalol and amiodarone) may be
tried because they may prove to be effective. The potential
benefit should be balanced by the potential risks of proar-
rhythmia and toxicity. Because ATs often occur in older
patients and in the context of structural heart disease, class Ic
agents should be used only after coronary artery disease is
excluded.
c. Catheter Ablation
Regardless of whether the arrhythmia is due to abnormal
automaticity, triggering, or micro–re-entry, focal AT is ab-
lated by targeting the site of origin of the AT.
Pooled data from 514 patients (124) who underwent
catheter ablation for focal AT showed an 86% success rate,
with a recurrence rate of 8% (119,125–129). In these series,
left atrial origins accounted for 18% of ATs, and 10% of
patients had multiple foci. The incidence of significant
complications is low (1% to 2%) in experienced centers, but
includes cardiac perforation, damage to the right and left
phrenic nerves and sinus node dysfunction. Ablation of AT
from the atrial septum or Koch’s triangle may produce AV
block.
For patients with drug refractory AT or incessant AT,
especially, when tachycardia-induced cardiomyopathy has
developed, the best therapy is catheter ablation of the focus.
Table 6 lists recommendations for treatment of focal atrial
tachycardia.
5. Multifocal Atrial Tachycardia
The diagnosis of MAT is made on the basis of finding an
irregular tachycardia characterized by three or more different
P-wave morphologies at different rates. The rhythm is always
irregular and frequently confused with AF, but the rate is not
excessively rapid. This arrhythmia is most commonly asso-
ciated with underlying pulmonary disease but may result
from metabolic or electrolyte derangements. It is seldom
caused by digitalis excess. There is seldom success using
antiarrhythmic agents, but a modicum of success has been
reported using calcium-channel blockers. Beta blockers are
usually contraindicated because of the presence of severe
underlying pulmonary disease. Therapy is instead directed at
correction of pulmonary disease and/or electrolyte abnormal-
ities. Chronic therapy often requires use of calcium-channel
blockers, as there is no role for DC cardioversion, antiar-
rhythmic drugs, or ablation.
F. Macro–Re-entrant Atrial Tachycardia
1. Isthmus-Dependent Atrial Flutter
Atrial flutter is characterized by an organized atrial rhythm
with a rate typically between 250 and 350 bpm. Electrophys-
iological studies have shown that this simple ECG definition
includes tachycardias using a variety of re-entry circuits. The
re-entry circuits often occupy large areas of the atrium and are
referred to as “macro–re-entrant.” The classic type of atrial
flutter (ie, typical flutter) is dependent on the cavotricuspid
isthmus (CTI). The precise type of flutter and, in particular,
dependence on a defined isthmus (see below) is an important
consideration for catheter ablation but does not alter the
initial approach to management.
a. Definitions of Cavotricuspid Isthmus–Dependent
Flutter Circuits
Isthmus-dependent flutter refers to circuits in which the
arrhythmia involves the CTI. The most common patterns
include a tachycardia showing a counterclockwise rotation
(ie, left anterior oblique view) around the tricuspid valve
(113). A less common pattern involves clockwise rotation
around the tricuspid annulus (ie, reverse typical flutter).
Counterclockwise atrial flutter is characterized electrocardio-
graphically by dominant negative flutter waves in the inferior
leads and a positive flutter deflection in lead V1 with
transition to a negative deflection in lead V6 at rates of 250
to 350 bpm (Figure 10). Clockwise isthmus-dependent flutter
shows the opposite pattern (ie, positive flutter waves in the
inferior leads and wide, negative flutter waves in lead V1,
transitioning to positive waves in lead V6) (Figure 11).
Patients may at times show unusual ECG patterns; hence,
confirmation of isthmus involvement can be made only by
entrainment pacing of the CTI during electrophysiological
studies.
b. Other CTI-Dependent Flutter Circuits
Isthmus-dependent flutter may also occur as double-wave
or lower-loop re-entry. Double-wave re-entry is defined as a
circuit in which two flutter waves simultaneously occupy the
usual flutter pathway (144). This arrhythmia is transient,
usually terminating within three to six complexes but may, on
rare occasions, deteriorate into AF (144). Lower-loop re-
entry is defined as a flutter circuit in which the re-entry
wavefront circulates around the inferior vena cava due to
conduction across the crista terminalis (145–147). The result-
ant circuit may produce unusual surface ECG patterns, but
these arrhythmias are still dependent on CTI conduction and,
hence, are amenable to ablation of the isthmus.
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c. Pathophysiology and Treatment Rationale
Cavotricuspid isthmus–dependent flutter is caused by a
macro–re-entrant right atrial circuit around the tricuspid
annulus. This circuit contains a propagating wavefront and an
excitable gap. The crista terminalis or sinus venosa (ie, area
between superior and inferior cava) is thought to be the
functional posterior barrier, whereas the tricuspid annulus
forms the anterior barrier. General mechanisms discussed
previously (see Section III) apply to flutter circuits. For
example, class Ia drugs have been shown to decrease con-
duction velocity and prolong refractoriness in the flutter
circuit; overall, these drugs tend to shorten the excitable gap.
Class Ic drugs depress conduction and can slow flutter. In
contrast, class III drugs (ie, ibutilide, dofetilide, or amiod-
arone) prolong refractoriness and may terminate flutter be-
cause the circulating wavefront encounters tissue that is
refractory. Rapid, atrial overdrive pacing can terminate the
arrhythmia when capturing stimuli penetrate the circuit early
enough to produce block in both directions (ie, antidromic
and orthodromic) in the circuit. In addition, the efficacy of
pacing can be enhanced by antiarrhythmic drug therapy that
facilitates penetration of the circuit by pacing impulses.
Direct current cardioversion is a very effective mode of
therapy because of rapid homogeneous depolarization of the
entire atrium. The practical implications of these findings are
discussed in the appropriate therapy sections.
d. Clinical Presentation
Patients with atrial flutter commonly present with acute
symptoms of palpitations, dyspnea, fatigue, or chest pain. In
contrast, this arrhythmia may also present with more insidi-
ous symptoms or conditions, such as exercise-induced fa-
tigue, worsening heart failure, or pulmonary disease.
Atrial flutter occurs in approximately 25% to 35% of
patients with AF and may be associated with more intense
symptoms owing to more rapid ventricular rates. In most
instances, patients with atrial flutter present with a two-to-one
AV-conduction pattern. The flutter rate is approximately 300
per minute with a ventricular response of 150 bpm. (Flutter
TABLE 6. Recommendations for Treatment of Focal Atrial Tachycardia*
Clinical Situation Recommendation Classification Level of Evidence References
Acute treatment†
A. Conversion
Hemodynamically
unstable patient
DC cardioversion I B
Hemodynamically stable patient Adenosine IIa C 123,130
Beta blockers IIa C 131,132
Verapamil, diltiazem IIa C 114,133
Procainamide IIa C
Flecainide/propafenone IIa C 133–136
Amiodarone, sotalol IIa C 116,135,137–140
B. Rate regulation (in absence of
digitalis therapy)
Beta blockers I C 131,132
Verapamil, diltiazem I C 141
Digoxin IIb C
Prophylactic therapy
Recurrent symptomatic AT Catheter ablation I B 124
Beta blockers, calcium-channel
blockers
I C
Disopyramide‡ IIa C 138
Flecainide/propafenone‡ IIa C 133,135,136,142,143
Sotalol, amiodarone IIa C 116,137–139
Asymptomatic or symptomatic
incessant Ats
Catheter ablation I B
Nonsustained and asymptomatic No therapy I C
Catheter ablation III C
The order in which treatment recommendations appear in this table within each class of recommendation does not necessarily reflect a preferred
sequence of administration. Please refer to text for details. For pertinent drug dosing information please refer to the ACC/AHA/ESC Guidelines on the
Management of Patients With Atrial Fibrillation.
*Excluded are patients with MAT in whom beta blockers and sotalol are often contraindicated due to pulmonary disease.
†All listed drugs for acute treatment are administered intravenously.
‡Flecainide, propafenone, and disopyramide should not be used unless they are combined with an AV-nodal–blocking agent.
AT indicates atrial tachycardia; DC, direct current; MAT, multifocal atrial tachycardia.
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with varying AV block can result in a grossly irregular
rhythm.) In exceptional circumstances, one-to-one AV con-
duction may occur in patients during exercise or in those with
rapid AV-nodal conduction and may be associated with
life-threatening symptoms. Class Ic drugs may, by slowing
the atrial rate, also cause one-to-one AV conduction and
should, therefore, be combined with AV-nodal–blocking
agents. Patients with accessory AV pathways capable of rapid
conduction also present with rapid ventricular rate and
life-threatening symptoms. Patients with impaired cardiac
function, in whom the coordinated contribution of atrial
function and regular rate are hemodynamically important, can
experience hemodynamic deterioration with the development
of atrial flutter even if the ventricular rate is not excessively
rapid. Atrial flutter, if untreated and accompanied by an
excessive ventricular rate, may also by itself promote cardio-
myopathy. Hemodynamic deterioration due to atrial flutter is
a problem late after repair of congenital heart disease,
particularly after Senning or Fontan operations (148,149). In
these patients, flutter is associated with a worse hemodynam-
ic profile and is a marker for worse prognosis.
e. Acute Treatment
Acute therapy for patients with atrial flutter depends on
clinical presentation. If the patient presents with acute hemo-
dynamic collapse or congestive heart failure (CHF), then
emergent DC-synchronized shock is indicated (Figure 12).
Atrial flutter can most often be successfully reverted to sinus
rhythm with energies less than 50 joules by using monophasic
shocks and with less energy using biphasic shocks. In most
instances, patients present with two-to-one or higher grades
of AV block and are hemodynamically stable. In this situa-
tion, the clinician may elect to use AV-nodal–blocking drugs
for rate control. Adequate rate control, albeit frequently
difficult to achieve, is especially important if conversion to
sinus rhythm is deferred. Atrial overdrive pacing, either
through the transesophageal route or with atrial electrodes, if
present, should be considered as an option for conversion to
sinus rhythm. For those with atrial flutter of more than 48
hours in duration, anticoagulant therapy is deemed important
prior to any mode of cardioversion (see below). Moreover, if
acute chemical cardioversion is planned, then rate control is
desirable because antiarrhythmic drugs, such as class Ic
agents, may slow the flutter rate and cause a paradoxical
increase in the ventricular response owing to decreased
concealed conduction into the AV node.
In approximately 60% of patients, atrial flutter occurs as
part of an acute disease process, such as exacerbation of
pulmonary disease, postoperative cardiac or pulmonary sur-
gery, or during acute myocardial infarction. If the patient
survives the underlying disease process, then chronic therapy
for the arrhythmia is usually not required after sinus rhythm
is restored. In summary, acute treatment of atrial flutter might
include the initial use of electrical pacing, DC or chemical
cardioversion, or AV-nodal–blocking agents. The anticipated
effects of these modalities are detailed below.
(1) Atrioventricular-Nodal–Blocking Agents. Available
randomized, controlled trials of AV-nodal–blocking agents
include patients with AF and atrial flutter. It is often difficult
to isolate the data for atrial flutter patients alone, and the
general impression is that rate control may be especially
difficult to achieve in patients with atrial flutter.
Two randomized, placebo-controlled, double-blinded trials
assessed use of IV diltiazem for rate control in patients with
AF or atrial flutter. Both studies showed rapid reductions in
heart rate, but this drug was less effective for rate control in
patients with atrial flutter compared with AF. Hypotension
was the chief adverse effect for the group as a whole,
occurring in approximately 10% of patients. A prospective,
randomized, open-labeled trial compared IV diltiazem with
IV digoxin for rate control. Rate control was usually achieved
within 30 minutes with IV diltiazem compared with more
than 4 hours with IV digoxin.
Intravenous verapamil is also efficacious in slowing the
ventricular rate. One prospective, randomized, double-
blinded crossover trial compared the safety and efficacy of IV
diltiazem and IV verapamil for patients with either AF (7
Figure 12. Management of atrial flutter
depending on hemodynamic stability.
Attempts to electively revert atrial flutter
to sinus rhythm should be preceded and
followed by anticoagulant precautions, as
per AF. AF indicates atrial fibrillation; AV,
atrioventricular; CHF, congestive heart
failure; DC, direct current; MI, myocardial
infarction.
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patients) or atrial flutter (10 patients) and decreased ejection
fraction. In this relatively small sample, both drugs had
comparable efficacy in terms of rate control and effect on
systolic function. The incidence of symptomatic hypotension,
however, was significantly higher for those initially random-
ized to IV verapamil.
The decrease in heart rate achieved with calcium-channel
blockers is similar to that observed for IV beta blockers. A
randomized, open-labeled study comparing IV digoxin to IV
amiodarone showed the superiority of IV amiodarone for
more rapid achievement of rate control. Intervenous amiod-
arone, however, appears to be less effective than IV calcium-
channel or beta blockers because adequate rate control (ie,
fewer than100 bpm) was not achieved for 6 hours. In
addition, IV calcium-channel blockers, beta blockers, or
amiodarone are seldom associated with conversion of atrial
flutter to sinus rhythm.
(2) Acute Intravenous Drugs for Pharmacologic Conver-
sion. A number of drugs have been shown to be effective in
conversion of atrial flutter to sinus rhythm.
(i) INTRAVENOUS IBUTILIDE. Placebo-controlled IV ibutilide
trials show an efficacy rate of 38% to 76% for conversion of
atrial flutter to sinus rhythm. In these studies, conversion
rates of atrial flutter were not related to duration of the
arrhythmia. For patients who responded to ibutilide, the mean
time to conversion was 30 minutes. The incidence of sus-
tained polymorphic VT for the group as a whole was 1.2% to
1.7%; for nonsustained VT (not requiring DC cardioversion),
the incidence was 1.8% to 6.7%. Randomized, double-
blinded studies comparing IV ibutilide and IV procainamide
are available (150). In the largest study available (150), the
efficacy of IV ibutilide was significantly greater than that of
IV procainamide for patients with atrial flutter—13 out of 17
patients (76%) versus 3 out of 22 (14%). One patient treated
with ibutilide developed polymorphic VT, while 7 of those
treated with procainamide developed hypotension. Procain-
amide was administered at a faster infusion rate in this study
than what is recommended, perhaps accounting for the
hypotension. Intravenous ibutilide should not be taken by
patients with severe structural cardiac diseases or prolonged
QT interval, or in those with underlying sinus node disease.
(ii) INTRAVENOUS CLASS IC DRUGS. Several single-blinded,
randomized, controlled trials comparing IV flecainide with
either IV propafenone or IV verapamil have shown relatively
poor efficacy for acute conversion. In one study, only 13% of
patients converted after IV flecainide administration; 40%
responded to propafenone (not statistically significant); and
only 5% reverted with verapamil. Similar results were found
in one additional randomized study comparing IV flecainide
with propafenone. Adverse effects included QRS widening,
dizziness, and paresthesias.
(iii) INTRAVENOUS SOTALOL. A randomized trial of IV
sotalol versus placebo for patients with SVT included only a
limited number of patients with atrial flutter. The conversion
rate varied from 20% to 40%, depending on the sotalol dose,
but was not different from placebo. Adverse effects included
hypotension and dyspnea. A large double-blinded, random-
ized trial involving 308 patients compared IV sotalol with IV
ibutilide for conversion of patients with AF or atrial flutter to
sinus rhythm (151). High-dose (2 mg) ibutilide was more
effective than sotalol (1.5 mg/kg) in conversion of patients
with atrial flutter (70% versus 19%) to sinus rhythm.
A review of the existing literature for IV antiarrhythmic
drugs taken by patients with atrial flutter suggests that
dofetilide or ibutilide are more effective than sotalol or class
I agents but are associated with a significant incidence of
torsades de pointes (1.5% to 3%). Controlled trials have
demonstrated the greater efficacy of IV class III agents (eg,
dofetilide, ibutilide) compared with IV amiodarone or class Ia
(eg, procainamide) or class Ic agents (eg, flecainide,
propafenone). Neither IV AV-nodal–blocking agents nor
amiodarone appears to be effective for arrhythmia conver-
sion, but they may be effective in rate control.
(3) Acute Nonpharmacologic Therapy
(i) EXTERNAL DIRECT CURRENT CARDIOVERSION. The suc-
cess rate for external DC cardioversion for patients with
flutter is between 95% and 100%. Conversion can often be
achieved with relatively small amounts of energy (ie, 5 to 50
joules), especially when biphasic wave forms are used, but
higher-energy initial shocks are warranted for emergent
cardioversion of patients with hemodynamic embarrassment.
Direct current cardioversion is the procedure of choice when
rapid termination of flutter is required.
(ii) ATRIAL OVERDRIVE PACING. The use and efficacy of
rapid atrial pacing to terminate atrial flutter has been long
established, and a comprehensive review showed a cumula-
tive success rate of 82% (range 55% to 100%). Overdrive
pacing is particularly useful in atrial flutter after cardiac
surgery, as these patients frequently have epicardial atrial
pacing wires. A number of studies have demonstrated the
efficacy of transesophageal pacing (152,153). In addition, it
has been clearly shown that use of antiarrhythmic drugs,
including procainamide (153), ibutilide, and propafenone,
may facilitate conversion of atrial flutter by pacing because
they facilitate impulse penetration of the flutter circuit and
reduce the risk of provoking AF (152). Moreover, high-
frequency atrial pacing or overdrive pacing with atrial extra-
stimuli have been shown to be effective in cases in which
atrial overdrive alone is not effective, an option available in
most modern pacemaker technologies. It is important to
recognize that atrial overdrive pacing may result in the
induction of sustained AF. In addition, periods of AF may
precede conversion to sinus rhythm.
f. Chronic Pharmacologic Treatment
(1) Class I Drugs. It is difficult to evaluate long-term
antiarrhythmic therapy for patients with atrial flutter be-
cause most studies combine patients with AF and atrial
flutter without specifying the results for each arrhythmia.
Review of the flecainide database showed the long-term
efficacy of this drug to be 50% for patients with atrial
flutter, but the results were available for only 36 patients.
Randomized, prospective, long-term trials comparing fle-
cainide and quinidine are available for patients with AF or
atrial flutter. No mention is made of patients with atrial
flutter as a distinct group, but the incidence of adverse side
effects for the group as a whole was significantly higher
with quinidine compared with flecainide. Beta blockers or
calcium-channel blockers should always be used in con-
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junction with class Ic agents for treatment of patients with
atrial flutter because the class Ic drugs may slow the flutter
rate and encourage one-to-one AV conduction.
(2) Class III Drugs. The efficacy of oral dofetilide has been
assessed in several randomized, placebo-controlled trials
(154,155). At the highest dose of dofetilide tested (500 g
twice per day), maintenance of sinus rhythm more than or
equal to 350 days occurred in 73% of patients with atrial
flutter compared with 40% of patients with AF. Contrain-
dications for dofetilide include creatinine clearance less
than 20, hypokalemia, hypomagnesemia, and prolonged
QT at baseline. Other randomized dose-titration studies
have been reported (156) (ie, sotalol), but, unfortunately,
results for the atrial flutter patients are not distinguished
from those with AF.
g. Role of Anticoagulant Therapy for Patients With
Atrial Flutter
The role of anticoagulant therapy for patients with AF is
determined on the basis of a number of prospective, random-
ized trials. Such trials are not available for patients with atrial
flutter. It was initially thought, on the basis of observational
studies, that the risk of embolization during cardioversion for
atrial flutter was negligible. Observational studies, however,
have shown a significant risk of embolization for these
patients, ranging from 1.7% to 7% (157,158).
In addition, a number of studies (159) have shown that the
incidence of atrial echo-dense material or clot varies from 0%
to 34% in nonanticoagulated patients with atrial flutter. The
incidence of echo-dense material or clot increases with atrial
flutter duration longer than or equal to 48 hours. Another area
of concern is the finding of atrial stunning after conversion of
atrial flutter, which appears to persist for several weeks (160).
In several studies, risk factors for development of embolic
events were similar to those described for AF (158).
In a collective review of the risk of embolization after
DC cardioversion for atrial flutter, the risk of embolism for
inadequately anticoagulated patients was 2.2%, signifi-
cantly lower than that reported for patients with AF (5% to
7%) (158). Although randomized, controlled trials of
thromboembolic prophylaxis for atrial flutter are not avail-
able, it is our consensus that the guidelines for anticoag-
ulation for patients with AF should be extended to those
with atrial flutter (144,161). Cardioversion— electrical,
chemical, or by ablation—should thus be considered only
if the patient is anticoagulated (international normalized
ratio [INR] equals 2 to 3), the arrhythmia is less than 48
hours in duration, or the transesophageal echocardiography
(TEE) shows no atrial clots. Negative TEE should be
followed by anticoagulation, as by itself it is not protective
against thromboembolism.
h. Catheter Ablation of the Cavotricuspid Isthmus for
Isthmus-Dependent Flutter
A technique for placing lesions between the tricuspid annulus
and the inferior vena cava to block the atrial flutter circuit and
cure patients with atrial flutter is available. Initially, success was
deemed present when ablation simply terminated the arrhythmia.
Using more stringent criteria to prove the existence of bidirec-
tional conduction block in the CTI results in better chronic
success rates (90% to 100%) (162,163). One prospective, ran-
domized study compared chronic oral antiarrhythmic therapy (in
61 patients with atrial flutter) to RF ablation (164). After a mean
follow-up of 21 plus or minus 11 months, only 36% of patients
treated with drugs compared with 80% of those treated with
catheter ablation remained in sinus rhythm. In addition, 63% of
patients in the drug-treatment group required one or more
hospitalizations, compared with 22% for those treated with
ablation. Quality of life was significantly improved in those
treated with ablation.
A number of studies have documented that patients with
AF who are treated with propafenone, flecainide, or amiod-
arone have a 15% to 20% risk of developing atrial flutter
(165–167). Prospective trials have shown that, if atrial flutter
becomes the dominant rhythm, then ablation of the CTI and
continued use of the antiarrhythmic drug result in a decreased
incidence of atrial flutter and facilitate the pharmacologic
management of AF (168,169). The incidence of AF after
successful ablation of the CTI flutter circuit varies, depending
on the presence of AF before ablation. For patients with a
history of only atrial flutter, the occurrence of AF over a
follow-up of 18 plus or minus 14 months was only 8%. In
contrast, for those with a history (follow-up 20 plus or minus
14 months) of both AF and predominant atrial flutter, the
recurrent rate of AF was 38%; whereas AF recurred in 86%
of those in whom AF predominated prior to ablation. It
appears that the best results of catheter ablation are achieved
in patients who have sole or predominant atrial flutter.
i. Treatment of Atrial Flutter in Special Circumstances
Atrial fibrillation is the most common arrhythmia, occur-
ring in 20% to 50% of patients who have undergone surgery,
depending on the nature of the surgery (ie, higher incidence
with mitral valve surgery). Likewise, atrial flutter also occurs
after cardiac surgery. Pathogenetic factors that may be in-
volved in the development of postoperative flutter include
pericarditis, a change in autonomic tone, or atrial ischemia.
Because atrial electrodes are usually left in place after cardiac
surgery, atrial overdrive pacing for conversion to sinus
rhythm is often a useful therapeutic technique to restore sinus
rhythm. If this approach fails, then a number of antiarrhyth-
mic drugs have been utilized, and a number of prospective,
randomized, controlled trials have been published using a
variety of agents. One randomized, placebo-controlled, drug-
titration trial used IV ibutilide for 101 postoperative patients
with atrial flutter (170). The conversion rate for atrial flutter
was 78% (44% for those with AF) and usually occurred
within 90 minutes of the infusion. Polymorphic VT was
observed in 1.8% of the patients and typically occurred within
several minutes of the ibutilide infusion. Intravenous dofeti-
lide has also been reported to be effective for patients with
postoperative AF or atrial flutter.
Atrial flutter may occur in patients with a variety of
comorbid conditions. These include chronic lung disease,
acute pneumonia, after pulmonary surgery, or as a complica-
tion of acute myocardial infarction. Rate control may be
achieved with either AV-nodal–blockers or IV amiodarone
(171). If the arrhythmia is associated with severe CHF or
hypotension, then urgent DC cardioversion is appropriate.
2. Non–Cavotricuspid Isthmus–Dependent Atrial Flutter
Atrial flutter caused by macro–re-entry circuits that do not use
the CTI are less common than CTI-dependent atrial flutter. Most
are related to an atrial scar that creates conduction block and a
central obstacle for re-entry. Prior cardiac surgery involving the
atrium, such as repair of congenital heart disease, mitral valve
surgery, or the atrial maze procedure, is a common cause. The
resulting arrhythmias are referred to as “lesion-related macro–
re-entrant ATs (113,172–175).”
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Although CTI-dependent flutter is the most common un-
derlying mechanism in these circumstances, it often coexists
with incisional macro–re-entrant ATs, resulting in multiple
re-entry circuits.
The appearance of the flutter waves on ECG usually differs
from CTI-dependent flutter but can resemble typical patterns
(see Figures 10 and 11) (113). In some cases, discrete P
waves are difficult to identify, possibly because of extensive
atrial scar. Definitive diagnosis requires intracardiac
mapping.
a. Catheter Ablation and Mapping of Non–Cavotricuspid
Isthmus–Dependent Flutter
Ablation of non–CTI-dependent flutter can be substantially
more difficult than for CTI-dependent flutter. When this type
of atrial flutter is suspected, such as in patients with congen-
ital heart disease who have had surgery, referral to an
experienced center should be considered. Cavotricuspid isth-
mus–dependent flutter is common in patients with prior atrial
surgery, and both CTI- and non–CTI-dependent macro–re-
entry circuits often coexist in a single patient (173,176-180).
Successful ablation is dependent on identifying a critical
portion of the re-entry circuit where it can be interrupted with
either one or a line of RF applications.
Surgical incisions in the right atrium for repair of atrial
septal defects (ASDs) are probably the most common cause
of lesion-related re-entry in adults (113,172,173,176-183).
The incision is often placed in the lateral right atrium; the
re-entry wavefront circulates around the incision. A line of
ablation lesions extending from the inferior margin of the scar
to the inferior vena cava, or from the superior margin of the
scar to the SVC, can interrupt the circuit, but it can also be
difficult to complete.
In six series, including 134 patients (predominantly young
adults with various types of surgically corrected congeni-
tal heart disease), ablation abolished arrhythmia recur-
rences in 50% to 88% of patients during average follow-up
periods of up to 2 years (172,176 –178). Complications of
diaphragmatic paralysis caused by phrenic nerve injury
and thromboembolism after conversion from atrial flutter
have occurred.
Macro–re-entry circuits occur in the left atrium, but are much
less common than right atrial circuits (113,180,184,185). Abla-
tion can be effective, but the number of patients studied is small
and the efficacy and adverse effects of ablation are not yet well
defined (184). Tables 7 and 8 list recommendations for acute and
long-term management of atrial flutter.
TABLE 7. Recommendations for Acute Management of Atrial Flutter
Clinical Status/Proposed Therapy Recommendation* Classification Level of Evidence References
Poorly tolerated
● Conversion DC cardioversion I C   
● Rate control Beta blockers IIa C   
Verapamil or diltiazem IIa C   
Digitalis† IIb C   
Amiodarone IIb C   
Stable flutter
● Conversion Atrial or transesophageal pacing I A 152,153,186–188
DC cardioversion I C 189
Ibutilide‡ IIa A 192,193
Flecainide§ IIb A 190,191
Propafenone§ IIb A 190,191
Sotalol IIb C 151,194
Procainamide§ IIb A 150
Amiodarone IIb C 23,195
● Rate control Diltiazem or verapamil I A 19,196–198
Beta blockers I C 197
Digitalis† IIb C 196
Amiodarone IIb C 195
The order in which treatment recommendations appear in this table within each class of recommendation does not necessarily
reflect a preferred sequence of administration. Please refer to text for details. For pertinent drug dosing information please refer to
the ACC/AHA/ESC Guidelines on the Management of Patients With Atrial Fibrillation.
Cardioversion should be considered only if the patient is anticoagulated (INR equals 2 to 3), the arrhythmia is less than 48 hours
in duration, or the TEE shows no atrial clots.
*All drugs are administered intravenously.
†Digitalis may be especially useful for rate control in patients with heart failure.
‡Ibutilide should not be taken by patients with reduced LV function.
§Flecainide, propafenone, and procainamide should not be used unless they are combined with an AV-nodal–blocking agent.
AV indicates atrioventricular; DC, direct current; INR, international normalized ratio; LV, left ventricular; TEE, transesophageal
echocardiography.
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VI. Special Circumstances
A. Pregnancy
Premature atrial beats are observed in approximately 50% of
patients during pregnancy, but they are generally benign and
well tolerated. Although sustained arrhythmias are relatively
rare (2 to 3 per 1000) in those who have supraventricular
arrhythmias, symptomatic exacerbation of paroxysmal SVT
occurs during pregnancy in approximately 20%.
The major concern during treatment of SVT during preg-
nancy is the potential for adverse effects on the fetus, as all
commonly used antiarrhythmic drugs cross the placental
barrier to some extent. Although the first 8 weeks after
conception is the period associated with the greatest terato-
genic risk, other adverse effects may occur with drug expo-
sure later in pregnancy. The major concern with antiarrhyth-
mic drugs taken during the second and third trimesters is the
adverse effect on fetal growth and development as well as the
risk of proarrhythmia. Several of the physiological changes
that occur during pregnancy, such as increased cardiac output
and blood volume, decreased serum protein concentration,
alterations in gastric secretion and motility, and hormonal
stimulation of liver enzymes, can affect absorption, bioavail-
ability, and elimination of many drugs. More careful moni-
toring of the patient and dose adjustments are, therefore,
necessary because the above-mentioned changes vary in
magnitude during different stages of pregnancy (202).
As with many other drugs used in pregnancy, use of certain
antiarrhythmic agents has crept into common practice be-
cause of an absence of reported ill effects, rather than as a
result of controlled studies. All antiarrhythmic drugs should
be regarded as potentially toxic to the fetus and should be
avoided if possible, especially during the first trimester. All
currently available antiarrhythmic drugs that are used for
SVT are categorized as class C drugs (using the US Food and
Drug Administration [FDA] drug classification system), ex-
cept for sotalol (a class B agent) and for atenolol and
amiodarone (class D agents).
In patients with mild symptoms and structurally normal
hearts, no treatment other than reassurance should be pro-
vided. Antiarrhythmic drug therapy should be used only if
symptoms are intolerable or if the tachycardia causes hemo-
dynamic compromise.
Catheter ablation should be recommended in women with
symptomatic tachyarrhythmias before they contemplate preg-
nancy. Because of the potential problem of recurring
tachyarrhythmias during pregnancy, the policy of withdraw-
ing antiarrhythmic drugs and resuming them later can be
recommended only as an alternative in selected cases. A
large-scale clinical experience with catheter ablation proce-
dures performed during pregnancy will never be reported,
although fetal radiation dose and risk from the procedures
have been calculated (203). Catheter ablation is the procedure
of choice for drug-refactory, poorly tolerated SVT. If needed,
it should be performed in the second trimester.
1. Acute Conversion of Atrioventricular Node–Dependent
Tachycardias
Intravenous adenosine is the drug of choice if vagal maneu-
vers fail to terminate an episode of PSVT. This drug has been
used safely in pregnant women, although most of the reports
TABLE 8. Recommendations for Long-Term Management of Atrial Flutter
Clinical Status/Proposed Therapy Recommendation Classification Level of Evidence References
First episode and well-tolerated atrial flutter Cardioversion alone I B 189
Catheter ablation* IIa B 164
Recurrent and well-tolerated atrial flutter Catheter ablation* I B 162,163,199
Dofetilide IIa C 154,155
Amiodarone, sotalol, flecainide,†‡
quinidine,†‡ propafenone,†‡
procainamide,†‡ disopyramide†‡
IIb C 23,156,200
Poorly tolerated atrial flutter Catheter ablation* I B 162,163,199
Atrial flutter appearing after use of class Ic
agents or amiodarone for treatment of AF
Catheter ablation* I B 168,169
Stop current drug and use another IIa C
Symptomatic non–CTI-dependent flutter
after failed antiarrhythmic drug therapy
Catheter ablation* IIa B 176–178
The order in which treatment recommendations appear in this table within each class of recommendation does not necessarily reflect a preferred
sequence of administration. Please refer to text for details. For pertinent drug dosing information please refer to the ACC/AHA/ESC Guidelines on the
Management of Patients With Atrial Fibrillation.
*Catheter ablation of the AV junction and insertion of a pacemaker should be considered if catheter ablative cure is not possible and the patient
fails drug therapy.
†These drugs should not be taken by patients with significant structural cardiac disease. Use of anticoagulants is identical to that described for
patients with AF (http://www.acc.org/clinical/guidelines/atrial_fib/af_index.htm).201
‡Flecainide, propafenone, procainamide, quinidine, and disopyramide should not be used unless they are combined with an AV-nodal–blocking
agent.
AF indicates atrial fibrillation; AV, atrioventricular; CTI, cavotricuspid isthmus.
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of adenosine administration were in the second and third
trimesters (202).
If adenosine fails, then IV propranolol or metoprolol are
recommended. Intravenous administration of verapamil may
be associated with a greater risk of maternal hypotension and
subsequent fetal hypoperfusion.
Available data suggest that DC cardioversion is safe in all
phases of pregnancy and can be used when necessary.
2. Prophylactic Antiarrhythmic Drug Therapy
If prophylactic drug therapy is needed, then digoxin or a
beta-blocking agent (ie, propranolol or metoprolol) is the
first-line agent. The experience with digoxin is extensive, and
it is considered one of the safest antiarrhythmic drugs to take
during pregnancy (202); however, its efficacy for arrhythmia
treatment or prophylaxis has never been demonstrated. Propran-
olol and metoprolol are generally considered to be safe but are
best avoided in the first trimester. Rare cases of adverse effects
on the fetus, including bradycardia, hypoglycemia, premature
labor, and metabolic abnormalities, have been reported but may
be secondary to fetal distress in high-risk pregnancies. Prospec-
tive, randomized studies have failed to demonstrate a higher
incidence of these complications with beta-blocking agents as
compared with placebo. The potential for intrauterine growth
retardation has been reported with propranolol and has raised
concerns, especially when it is taken in the first trimester (202).
Later studies reported growth retardation in babies receiving
atenolol in the first trimester and a higher prevalence of preterm
delivery (204). Atenolol is, therefore, classified as a category D
agent by the FDA. In view of these results, beta blockers should
be avoided during the first trimester, if possible. Beta blockers
with selective B1 properties are theoretically preferable because
they may interfere less with peripheral vasodilatation and uterine
relaxation.
If the above-mentioned drugs fail, then sotalol may be
considered. Although sotalol has been used successfully during
pregnancy for other indications, the experience is limited; so,
caution is still advised. The reported experience with flecainide
is also limited, but it appears to be relatively safe during
pregnancy (205). The experience with propafenone is even more
limited, although no adverse effects to the fetus have been
reported when it is taken during the third trimester. Quinidine is
considered to be relatively well tolerated, although isolated cases
of adverse effects, such as fetal thrombocytopenia and eighth-
nerve toxicity, have been reported (202). Procainamide is con-
sidered to be well tolerated and appears to be relatively safe for
short-term therapy. The use of amiodarone, a category D agent,
in pregnancy should be restricted to arrhythmias that are resistant
to other drugs or are life threatening (206). Table 9 lists
recommendations for treatment strategies for SVT during
pregnancy.
It should be emphasized that these recommendations rely
mainly on observational data; the cited references are, there-
fore, not all inclusive.
B. Supraventricular Tachycardias in Adult
Patients With Congenital Heart Disease
1. Introduction
An increasing number of patients with congenital heart
disease are surviving to adulthood. Supraventricular arrhyth-
TABLE 9. Recommendations for Treatment Strategies for SVT During Pregnancy
Treatment Strategy Recommendation Classification
Level of
Evidence
Acute conversion of PSVT Vagal maneuver I C
Adenosine I C
DC cardioversion I C
Metoprolol, propranolol IIa C
Verapamil IIb C
Prophylactic therapy Digoxin I C
Metoprolol* I B
Propranolol* IIa B
Sotalol,* flecainide† IIa C
Quinidine, propafenone,† verapamil IIb C
Procainamide IIb B
Catheter ablation IIb C
Atenolol‡ III B
Amiodarone III C
The order in which treatment recommendations appear in this table within each class of
recommendation does not necessarily reflect a preferred sequence of administration. Please refer to
text for details. For pertinent drug dosing information please refer to the ACC/AHA/ESC Guidelines on
the Management of Patients With Atrial Fibrillation.
*Beta-blocking agents should not be taken in the first trimester, if possible.
†Consider AV-nodal– blocking agents in conjunction with flecainide and propafenone for certain
tachycardias (see Section V).
‡Atenolol is categorized in class C (drug classification for use during pregnancy) by legal authorities
in some European countries.
AV indicates atrioventricular; DC, direct current; PSVT, paroxysmal supraventricular tachycardia.
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mias are an important cause of morbidity and, in some of
these patients, mortality. In patients who have not had
operative repair of their malformation, AF and atrial flutter
are the most common arrhythmias. Increased atrial filling
pressures may contribute to the cause of AF or atrial flutter.
Surgical repairs that place incisions in the atria predispose to
incisional-related atrial flutter late after surgery.
Many patients warrant referral to an experienced spe-
cialist. The new development of atrial arrhythmias can be
an indication of deteriorating hemodynamic function,
which in some cases warrants specific investigation and
occasionally operative treatment. An SVT itself dramati-
cally impairs hemodynamic performance in some patients.
Coexistent sinus node dysfunction is common after surgi-
cal repair of many of these conditions and can be further
aggravated by antiarrhythmic therapy, requiring pace-
maker implantation to allow management of the supraven-
tricular arrhythmia. Cardiac malformations often increase
the difficulty of pacemaker implantation and catheter
ablation procedures. The presence of intracardiac shunts
creates a risk of systemic embolism from clots that may
form on pacing leads even though they are in the right-
sided (ie, systemic venous) cardiac chambers.
2. Specific Disorders
a. Atrial Septal Defect
Atrial fibrillation or atrial flutter occurs in approximately 20%
of adults who have an unrepaired ASD (207,208). Atrial fibril-
lation, rather than atrial flutter, predominates in the majority;
incidence increases with patient age. Surgical or percutaneous
closure of ASDs associated with pulmonary blood flow/systemic
blood flow (Qp/Qs) more than 1.5 and or symptoms before the
age of 40 years may reduce atrial arrhythmias but has little effect
after the age of 40 years (207–209).
Gatzoulis and coworkers retrospectively reviewed 218
adults who had surgical closure of an isolated ASD (207).
Sustained atrial flutter or AF was present in 19% of patients
prior to surgery, 5% had atrial flutter, 2.8% had AF and atrial
flutter, and 11% had AF. During a mean follow-up of 3.8
years, 60% of patients with preoperative AF or atrial flutter
continued to have arrhythmias, and new AF or atrial flutter
developed in 2.3% of patients. All of the patients with
persistent arrhythmias and those who developed new atrial
arrhythmias were older than 40 years of age at the time of
repair. None of the 106 patients younger than 40 years of age
at the time of surgery had late atrial arrhythmias during this
follow-up period (P0.008).
Attie and coworkers randomized 521 adults older than 40
years of age who had isolated secundum or sinus venosal
ASDs with a Qp/Qs more than 1.7 and pulmonary artery
systolic pressure less than 70 mm Hg to surgical closure
versus medical therapy (208). Prior to randomization, 21% of
patients had a history of AF or atrial flutter managed with rate
control and anticoagulation, and 5% had a history of other
types of SVT. During a median follow-up of 7.3 years, new
atrial flutter or AF developed in 7.4% of patients in the
surgical group and 8.7% of patients in the medical group.
Cerebral embolic events occurred in 2.1% of patients. The
risk was not different between the surgical and medically
treated patients.
Management of atrial flutter is the same as described in
Section V-F. In patients who have not had surgical repair,
atrial flutter is likely to be dependent on conduction through
the CTI and susceptible to catheter ablation. If closure of the
ASD is not warranted by hemodynamic criteria, then catheter
ablation of the atrial flutter is preferable to surgical closure of
the ASD, which is unlikely to abolish the atrial flutter. If
closure of the septal defect is warranted in a patient with atrial
flutter, then electrophysiological study with catheter ablation
prior to surgery may still be considered or ablation of the
atrial flutter isthmus may be performed during surgery in a
center with experience in arrhythmia surgery.
In patients with prior surgical repair, both CTI-dependent and
non–CTI-dependent (so-called “incisional” or scar) atrial flutter
occur and can coexist in a single patient (113,172,173,176,178–
183,210). Management is as discussed above. If catheter abla-
tion is warranted, then the possibility that the flutter will have a
non–CTI-dependent mechanism should be considered. Ablation
may be best performed in an experienced center with advanced,
three-dimensional mapping equipment for defining non–CTI-
dependent arrhythmias.
b. Transposition of the Great Vessels
Atrial arrhythmias are uncommon late after arterial switch
procedures. The Mustard and Senning repairs reroute sys-
temic venous blood to the morphological LV that is con-
nected to the pulmonary artery, and they reroute the pulmo-
nary venous blood to the morphological right ventricle that is
connected to the aorta. The atrial surgery is extensive, and
sinus node dysfunction is common (211,212). Of 478 patients
who survived the perioperative period after Mustard repair in
a study reported by Gelatt and coworkers, atrial flutter
subsequently occurred in 14%, and ectopic AT occurred in
1% (3 patients). The actuarial rate of atrial flutter at 20 years
after repair was 24%. An even greater incidence of atrial
arrhythmias was observed in earlier series.
Loss of coordinated atrial activity and acceleration of rate
can produce severe symptoms and hemodynamic compro-
mise. Development of atrial arrhythmias is also associated
with impaired ventricular function (149,213). For these rea-
sons, development of atrial arrhythmias has been associated
with an increased risk of death and sudden death in some, but
not all, studies (212).
Acute management of rapid SVT is as discussed above (see
Sections IV and V). These arrhythmias tend to be recurrent,
and attempts to maintain sinus rhythm are usually warranted
due to the hemodynamic compromise produced by the ar-
rhythmia. Associated ventricular dysfunction and risk of
sudden death and sinus node dysfunction can complicate
selection of antiarrhythmic drug therapy. Referral to a spe-
cialist with experience in the care of these patients is usually
warranted. Catheter ablation of the lesion related to the atrial
flutter can be effective but is more difficult than for patients
without structural heart disease and should be attempted only
at experienced centers (210).
c. Tetralogy of Fallot
Atrial incisions are commonly made at the time of repair,
predisposing to the late development of incisional-related
atrial flutter (148,214). During 35 years of follow-up after
repair 10% of patients developed atrial flutter, 11% devel-
oped sustained VT, and 8% died suddenly (214).
The sinus rhythm ECG shows RBBB in the vast majority
of patients, such that SVTs are conducted with RBBB
aberrancy. Ventricular tachycardia arises due to re-entry in
the region of the right ventricular outflow tract or infundib-
ular septum. Although most of these VTs have a QRS
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configuration resembling LBBB, the VT QRS resembles
RBBB in approximately 25% of patients. An RBBB config-
uration of the tachycardia is not, therefore, a reliable guide for
distinguishing a VT from an SVT. Atrial flutter precipitates
hemodynamic compromise in some patients. Acute manage-
ment is dictated by hemodynamic stability (see Section IV.
B). Establishment of the correct diagnosis is critical to guide
further management. Electrophysiological testing may be
required, and referral to a specialist is advised.
Atrial flutter can be CTI dependent or incisional related
(172,210). Development of atrial flutter can be an indication
of worsening ventricular function and tricuspid regurgitation
(131,148,214,215). Hemodynamic reassessment of the repair
and consideration for revision are sometimes warranted.
Chronic management is as discussed above.
d. Ebstein’s Anomaly of the Tricuspid Valve
Accessory AV and atriofascicular pathways occur in up to
25% of patients and are more often right sided and multiple
than in patients without the disorder (216–219). In addition to
AVRT, AF, atrial flutter, and ectopic AT can occur.
Right bundle-branch block is usually present and, in the
presence of a right-sided accessory pathway, ventricular
pre-excitation can mask the ECG evidence of RBBB. Thus,
patients may present with orthodromic AVRT with RBBB
aberrancy and, after termination of the arrhythmia, there may
be evidence of a right-sided accessory pathway causing
pre-excitation during sinus rhythm. Left bundle-branch
block–configuration tachycardias can be due to antidromic
AVRT or conduction over a bystander accessory pathway
during, for example, AT, AVRT, or atrial flutter.
The malformation can be mild, producing no symptoms.
Alternatively, tricuspid regurgitation and a large ASD can
cause cyanosis and hemodynamic compromise that may be
exacerbated by arrhythmias. Depending on the severity of the
malformation and the arrhythmia, SVTs can produce cyanosis
and severe symptoms or death. Sudden death can also occur
as a consequence of rapid repetitive conduction to the
ventricles during AF or atrial flutter when an accessory
pathway is present (219).
When hemodynamic consequences of the malformation
warrant operative correction and supraventricular arrhyth-
mias are present, arrhythmia management should be coordi-
nated with the surgical team (220). Preoperative electrophys-
iological evaluation is often warranted. Failure to address
potential accessory pathways can lead to recurrent arrhyth-
mias and instability in the perioperative period. Catheter
ablation prior to surgery is, therefore, recommended. Surgical
division of accessory pathways may be considered as an
option for selected patients in centers with experience.
In general, management of accessory pathways in Eb-
stein’s anomaly is as discussed in Section V-D. The associ-
ated malformation and common coexistence of multiple
accessory pathways, however, increase the difficulty of map-
ping and ablation. Of 65 patients reported in the Pediatric
Radiofrequency Ablation Registry, short-term success rates
ranged from 75% to 89%, depending on pathway location
(septal versus free wall); late recurrences occurred in up to
32% of patients (221).
e. Fontan Repairs
Incisional-related atrial flutter or AF occurs in up to 57% of
patients, depending on the particular type of repair (222,223).
Atrial arrhythmias can cause rapid hemodynamic deteriora-
tion and are associated with more heart failure. Acute
management is as discussed for atrial flutter above. Referral
to a specialist is advised. Catheter ablation can be effective
but is often difficult due to multiple circuits and should be
attempted only at experienced centers. In addition to the low
success rate of catheter ablation in the Fontan atriopulmonary
connection, there is a high rate of recurrence after initially
successful ablation procedures, limiting the usefulness of this
approach (210). Table 10 lists recommendations for treatment
of SVTs in adults with congenital heart disease.
C. Quality-of-Life and Cost Considerations
Improvement of quality of life is usually the major therapeu-
tic goal of treatment for SVT. Although it was reported early
that catheter ablation improves quality of life (227,228) and is
cost effective compared with other strategies, these studies
were observational rather than randomized or were limited to
more symptomatic patients on stable antiarrhythmic medical
therapy. A later study compared the effect on quality of life
between catheter ablation and pharmacologic therapy as an
initial strategy for patients with SVTs (229). Both treatments
improved quality of life and decreased frequency of disease-
specific symptoms, but ablation improved quality of life in
TABLE 10. Recommendations for Treatment of SVTs in Adults With Congenital Heart Disease
Condition Recommendation Classification
Level of
Evidence References
Failed antiarrhythmic drugs and
symptomatic:
● Repaired ASD Catheter ablation in an experienced center I C 172,174,175,178,181,210,224,225
● Mustard or Senning repair of
transposition of the great vessels
Catheter ablation in an experienced center I C 175,178,181,210
Unrepaired asymptomatic ASD not
hemodynamically significant
Closure of the ASD for treatment of the arrhythmia III C 208,209
Unrepaired hemodynamically
significant ASD with atrial flutter*
Closure of the ASD combined with ablation of the
flutter isthmus
I C
PSVT and Ebstein’s anomaly with
hemodynamic indications for
surgical repair
Surgical ablation of accessory pathways at the
time of operative repair of the malformation at an
experienced center
I C 220,226
*Conversion and antiarrhythmic drug therapy initial management as described for atrial flutter (see Section V-F).
ASD indicates atrial septal defect; PSVT, paroxysmal supraventricular tachycardia.
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more general health categories and resulted in complete
amelioration of symptoms in more patients (74% versus 33%)
than did medication. Potential long-term costs were similar
for medication and ablation (229). Among patients who had
monthly episodes of SVT, RF ablation was, however, the
more effective and less expensive therapy compared with
long-term drug therapy (230). Another prospective study
compared the long-term effects on health outcome of catheter
ablation and medical therapy as an initial treatment for
patients with newly documented PSVT, excluding those with
drug-refractory symptoms referred specifically for ablation
(231). At 5-year follow-up, patients who received ablation
had improved quality-of-life scores and a reduction in
disease-specific symptoms when compared with patients who
continued to take medical therapy. More patients reported
complete elimination of symptoms with ablation therapy
(70%) than did those taking medical therapy (43%). Over 5
years, the average cumulative cost for patients in the medical
therapy group was statistically significantly lower than in
patients initially treated with ablation therapy: $6249 plus or
minus $1421 per patient versus $7507 plus or minus $1098
per patient (231). It was concluded that patient preference
remains the critical determinant in choosing a particular
treatment in cases of mildly to moderately symptomatic
PSVT (231).
Baseline quality-of-life scores appear to be lower for
patients with atrial flutter and AF than for those with other
arrhythmias who are undergoing RF ablation. Several studies
have described improvement in symptoms and quality of life
after catheter ablation of atrial flutter (164,232–234). Abla-
tion of atrial flutter resulted in an improvement in quality of
life as well as reductions in symptom-frequency scores and
symptom-severity scores compared with preablation values
(234). There was a reduction in the number of patients
visiting accident and emergency departments, requiring car-
dioversion, and being admitted to a hospital for a rhythm
problem. Patients with atrial flutter and concomitant AF
before ablation and those with atrial flutter alone both derived
significant benefit from atrial flutter ablation (234). Others
reported that patients who had atrial flutter associated with
AF before ablation had less improvement than those without
AF (233). Moreover, in a prospective, randomized compari-
son of antiarrhythmic therapy versus first-line RF ablation in
patients with atrial flutter, the sense of well-being and
function in daily life improved after ablation but did not
change significantly in patients treated with drugs (164).
Ablation was associated with a better success rate and effect
on quality of life, a lower occurrence of AF, and a lower need
for rehospitalization at follow-up.
References
1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for
the management of patients with atrial fibrillation: executive summary:
a report of the American College of Cardiology/American Heart Asso-
ciation Task Force on Practice Guidelines and the European Society of
Cardiology Committee for Practice Guidelines and Policy Conferences
(Committee to Develop Guidelines for the Management of Patients With
Atrial Fibrillation) Developed in collaboration with the North American
Society of Pacing and Electrophysiology. Circulation 2001;104:
2118–50.
2. Baine WB, Yu W, Weis KA. Trends and outcomes in the hospitalization
of older Americans for cardiac conduction disorders or arrhythmias,
1991–1998. J Am Geriatr Soc 2001;49:763–70.
3. Orejarena LA, Vidaillet H, Jr, DeStefano F, et al. Paroxysmal supraven-
tricular tachycardia in the general population. J Am Coll Cardiol 1998;
31:150–7.
4. Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial
flutter in the general population. J Am Coll Cardiol 2000;36:2242–6.
5. Kwong KF, Schuessler RB, Green KG, et al. Differential expression of
gap junction proteins in the canine sinus node. Circ Res 1998;82:
604–12.
6. Wu J, Schuessler RB, Rodefeld MD, et al. Morphological and
membrane characteristics of spider and spindle cells isolated from rabbit
sinus node. Am J Physiol Heart Circ Physiol 2001;280:H1232–40.
7. Boyett MR, Honjo H, Yamamoto M, et al. Downward gradient in action
potential duration along conduction path in and around the sinoatrial
node. Am J Physiol 1999;276:H686–98.
8. Cheung DW. Electrical activity of the pulmonary vein and its interaction
with the right atrium in the guinea-pig. J Physiol 1981;314:445–56.
9. Cheung DW. Pulmonary vein as an ectopic focus in digitalis-induced
arrhythmia. Nature 1981;294:582–4.
10. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after
ablation of atrial flutter. J Am Coll Cardiol 1998;32:205–10.
11. Wu EB, Chia HM, Gill JS. Reversible cardiomyopathy after radiofre-
quency ablation of lateral free- wall pathway-mediated incessant
supraventricular tachycardia. Pacing Clin Electrophysiol 2000;23:
1308–10.
12. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA
guidelines for ambulatory electrocardiography: executive summary and
recommendations. a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Com-
mittee to Revise the Guidelines for Ambulatory Electrocardiography).
Circulation 1999;100:886–93.
13. Seidl K, Rameken M, Breunung S, et al. Diagnostic assessment of
recurrent unexplained syncope with a new subcutaneously implantable
loop recorder. Reveal-Investigators. Europace 2000;2:256–62.
14. Lee KL, Chun HM, Liem LB, et al. Effect of adenosine and verapamil
in catecholamine-induced accelerated atrioventricular junctional
rhythm: insights into the underlying mechanism. Pacing Clin Electro-
physiol 1999;22:866–70.
15. Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of
adenosine in patients with supraventricular tachycardia. Circulation
1999;99:1034–40.
16. Advanced cardiovascular life support: introduction to ACLS 2000:
overview of recommended changes in ACLS from the Guidelines 2000
Conference (abstr). Circulation 2000;102:I86–9.
17. Cairns CB, Niemann JT. Intravenous adenosine in the emergency
department management of paroxysmal supraventricular tachycardia.
Ann Emerg Med 1991;20:717–21.
18. Rankin AC, Brooks R, Ruskin JN, et al. Adenosine and the treatment of
supraventricular tachycardia. Am J Med 1992;92:655–64.
19. Waxman HL, Myerburg RJ, Appel R, et al. Verapamil for control of
ventricular rate in paroxysmal supraventricular tachycardia and atrial
fibrillation or flutter: a double-blind randomized cross-over study. Ann
Intern Med 1981;94:1–6.
20. Amsterdam EA, Kulcyski J, Ridgeway MG. Efficacy of cardioselective
beta-adrenergic blockade with intravenously administered metoprolol in
the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol
1991;31:714–8.
21. Das G, Tschida V, Gray R, et al. Efficacy of esmolol in the treatment
and transfer of patients with supraventricular tachyarrhythmias to
alternate oral antiarrhythmic agents. J Clin Pharmacol 1988;31:714–8.
22. Holt P, Crick JC, Davies DW, et al. Intravenous amiodarone in the acute
termination of supraventricular arrhythmias. Int J Cardiol 1985;8:67–79.
23. Hohnloser SH, Zabel M. Short- and long-term efficacy and safety of
flecainide acetate for supraventricular arrhythmias. Am J Cardiol 1992;
70:3A–9A.
24. Glatter KA, Dorostkar PC, Yang Y, et al. Electrophysiological effects of
ibutilide in patients with accessory pathways. Circulation 2001;104:
1933–9.
25. Gorgels AP, van den DA, Hofs A et al. Comparison of procainamide and
lidocaine in terminating sustained monomorphic ventricular tachycardia.
Am J Cardiol 1996;78:43–6.
1526 Blomström-Lundqvist et al. JACC Vol. 42, No. 8, 2003
ACC/AHA/ESC Guidelines for Management of SVA October 15, 2003:1493–531
26. Manz M, Mletzko R, Jung W, et al. Electrophysiological and haemo-
dynamic effects of lidocaine and ajmaline in the management of sus-
tained ventricular tachycardia. Eur Heart J 1992;13:1123–8.
27. Ho DS, Zecchin RP, Richards DA, et al. Double-blind trial of lignocaine
versus sotalol for acute termination of spontaneous sustained ventricular
tachycardia. Lancet 1994;344:18–23.
28. Part 1: Introduction to the International Guidelines 2000 for CPR and
ECC : a consensus on science. Circulation 2000;102:I1–11.
29. Boineau JP, Schuessler RB, Hackel DB, et al. Widespread distribution
and rate differentiation of the atrial pacemaker complex. Am J Physiol
1980;239:H406–15.
30. Scheinman MM, Levine JH, Cannom DS, et al., for the Intravenous
Amiodarone Multicenter Investigators Group. Dose-ranging study of
intravenous amiodarone in patients with life-threatening ventricular
tachyarrhythmias. Circulation 1995;92:3264–72.
31. Sharma AD, Klein GJ, Yee R. Intravenous adenosine triphosphate
during wide QRS complex tachycardia: safety, therapeutic efficacy, and
diagnostic utility. Am J Med 1990;88:337–43.
32. Buxton AE, Marchlinski FE, Doherty JU, et al. Hazards of intravenous
verapamil for sustained ventricular tachycardia. Am J Cardiol 1987;59:
1107–10.
33. Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist.
Heart 2000;83:627–33.
34. Steinherz L, Yalahom J. Cardiac toxicity. In: DeVita VT, Hellman S,
Rosenberg SA, editors. Cancer Principles and Practice of Oncology.
Philadelphia, PA: Lippincott Williams and Wilkins, 2001:2904–21.
35. Olgin J, Zipes D. Specific arrhythmias: diagnosis and treatment. In:
Braunwald E, Zipes D, editors. Heart Disease: A Textbook of Cardio-
vascular Medicine. Libby P. Philadelphia, PA: Saunders, 2001:815–89.
36. Asnis GM, Hameedi FA, Goddard AW, et al. Fluvoxamine in the
treatment of panic disorder: a multi-center, double-blind, placebo-
controlled study in outpatients. Psychiatry Res 2001;103:1–14.
37. Stein DJ, Stein MB, Goodwin W, et al. The selective serotonin reuptake
inhibitor paroxetine is effective in more generalized and in less gener-
alized social anxiety disorder. Psychopharmacology (Berl) 2001;158:
267–72.
38. van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the
selective serotonin reuptake inhibitors for social anxiety disorder (social
phobia): a meta-analysis of randomized controlled trials. Int Clin Psy-
chopharmacol 2000;15 Suppl 2:S15–23.
39. Schomig A, Kastrati A, Dirschinger J, et al. for the Stent versus Throm-
bolysis for Occluded Coronary Arteries in Patients with Acute Myo-
cardial Infarction Study Investigators. Coronary stenting plus platelet
glycoprotein IIb/IIIa blockade compared with tissue plasminogen acti-
vator in acute myocardial infarction. N Engl J Med 2000;343:385–91.
40. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.
3-year follow-up of patients randomised in the metoprolol in dilated
cardiomyopathy trial. Lancet 1998;351:1180–1.
41. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised
trial. Lancet 1999;353:9–13.
42. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system.
N Engl J Med 2001;344:501–9.
43. Cossu SF, Steinberg JS. Supraventricular tachyarrhythmias involving
the sinus node: clinical and electrophysiologic characteristics. Prog
Cardiovasc Dis 1998;41:51–63.
44. Sato T, Mitamura H, Murata M, et al. Electrophysiologic findings of a
patient with inappropriate sinus tachycardia cured by selective radiofre-
quency catheter ablation. J Electrocardiol 2000;33:381–6.
45. Mischke K, Stellbrink C, Hanrath P. Evidence of sinoatrial block as a
curative mechanism in radiofrequency current ablation of inappropriate
sinus tachycardia. J Cardiovasc Electrophysiol 2001;12:264–7.
46. Man KC, Knight B, Tse HF, et al. Radiofrequency catheter ablation of
inappropriate sinus tachycardia guided by activation mapping. J Am
Coll Cardiol 2000;35:451–7.
47. Lee RJ, Kalman JM, Fitzpatrick AP, et al. Radiofrequency catheter
modification of the sinus node for “inappropriate” sinus tachycardia.
Circulation 1995;92:2919–28.
48. Yee R, Guiraudon GM, Gardner MJ, et al. Refractory paroxysmal sinus
tachycardia: management by subtotal right atrial exclusion. J Am Coll
Cardiol 1984;3:400–4.
49. Esmailzadeh B, Bernat R, Winkler K, et al. Surgical excision of the
sinus node in a patient with inappropriate sinus tachycardia. J Thorac
Cardiovasc Surg 1997;114:861–4.
50. de Paola AA, Horowitz LN, Vattimo AC, et al. Sinus node artery
occlusion for treatment of chronic nonparoxysmal sinus tachycardia.
Am J Cardiol 1992;70:128–30.
51. Jayaprakash S, Sparks PB, Vohra J. Inappropriate sinus tachycardia
(IST): management by radiofrequency modification of sinus node. Aust
N Z J Med 1997;27:391–7.
52. Goya M, Iesaka Y, Takahashi A, et al. Radiofrequency catheter ablation
for sinoatrial node re-entrant tachycardia: electrophysiologic features of
ablation sites. Jpn Circ J 1999;63:177–83.
53. Tendera M, Wnuk-Wojnar AM, Kulakowski P, et al. Efficacy and safety
of dofetilide in the prevention of symptomatic episodes of paroxysmal
supraventricular tachycardia: a 6-month double-blind comparison with
propafenone and placebo. Am Heart J 2001;142:93–8.
54. Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out-of-
hospital self-administered single-dose oral drug treatment in the man-
agement of infrequent, well-tolerated paroxysmal supraventricular
tachycardia. J Am Coll Cardiol 2001;37:548–53.
55. Scheinman MM, Huang S. The 1998 NASPE prospective catheter
ablation registry. Pacing Clin Electrophysiol 2000;23:1020–8.
56. Clague JR, Dagres N, Kottkamp H, et al. Targeting the slow pathway for
atrioventricular nodal re-entrant tachycardia: initial results and
long-term follow-up in 379 consecutive patients. Eur Heart J 2001;
22:82–8.
57. Calkins H, Yong P, Miller JM, et al., for the Atakr Multicenter Inves-
tigators Group. Catheter ablation of accessory pathways, atrioventricular
nodal re-entrant tachycardia, and the atrioventricular junction: final
results of a prospective, multicenter clinical trial. Circulation 1999;99:
262–70.
58. Akhtar M, Jazayeri MR, Sra J, et al. Atrioventricular nodal re-entry:
clinical, electrophysiological, and therapeutic considerations. Circu-
lation 1993;88:282–95.
59. Mauritson DR, Winniford MD, Walker WS, et al. Oral verapamil for
paroxysmal supraventricular tachycardia: a long-term, double-blind ran-
domized trial. Ann Intern Med 1982;96:409–12.
60. Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal
supraventricular tachycardia: a randomized, double-blind comparison of
digoxin, propranolol and verapamil. Am J Cardiol 1984;54:1138–9.
61. Anderson JL, Platt ML, Guarnieri T, et al., for the Flecainide Supraven-
tricular Tachycardia Study Group. Flecainide acetate for paroxysmal
supraventricular tachyarrhythmias. Am J Cardiol 1994;74:578–84.
62. Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of
symptomatic paroxysmal supraventricular arrhythmias: a randomized,
placebo-controlled, crossover trial in patients tolerating oral therapy.
Ann Intern Med 1991;114:539–44.
63. Wanless RS, Anderson K, Joy M, et al. Multicenter comparative study
of the efficacy and safety of sotalol in the prophylactic treatment of
patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J
1997;133:441–6.
64. Henthorn RW, Waldo AL, Anderson JL, et al., for the Flecainide
Supraventricular Tachycardia Study Group. Flecainide acetate prevents
recurrence of symptomatic paroxysmal supraventricular tachycardia.
Circulation 1991;83:119–25.
65. UK Propafenone PSVT Study Group. A randomized, placebo-controlled
trial of propafenone in the prophylaxis of paroxysmal supraventricular
tachycardia and paroxysmal atrial fibrillation. Circulation 1995;92:
2550–7.
66. Gambhir DS, Bhargava M, Nair M, et al. Comparison of electrophysi-
ologic effects and efficacy of single-dose intravenous and long-term oral
amiodarone therapy in patients with AV nodal re-entrant tachycardia.
Indian Heart J 1996;48:133–7.
67. Bogun F, Knight B, Weiss R, et al. Slow pathway ablation in patients
with documented but noninducible paroxysmal supraventricular
tachycardia. J Am Coll Cardiol 1996;28:1000–4.
68. Hamdan MH, Dorostkar P, Scheinman M. Junctional tachycardia and
junctional rhythm. In: Zipes D, Jalife J, editors. Cardiac Electrophys-
iology: From Cell to Bedside. Philadelphia, PA: WB Saunders, 2000:
482–8.
69. Kuck KH, Kunze KP, Schluter M, et al. Encainide versus flecainide for
chronic atrial and junctional ectopic tachycardia. Am J Cardiol 1988;
62:37L–44L.
70. Paul T, Reimer A, Janousek J, et al. Efficacy and safety of propafenone
in congenital junctional ectopic tachycardia. J Am Coll Cardiol 1992;
20:911–4.
71. Maragnes P, Fournier A, Davignon A. Usefulness of oral sotalol for the
treatment of junctional ectopic tachycardia. Int J Cardiol 1992;35:165–7.
1527JACC Vol. 42, No. 8, 2003 Blomström-Lundqvist et al.
October 15, 2003:1493–531 ACC/AHA/ESC Guidelines for Management of SVA
72. Fidell J, Do-Ngoc D, Attuel P, et al. L’amiodarone dans le traitement des
troubles du rythme cardiaque de l’enfant. Arch Mal Coeur Vaiss 1973;
2:198–204.
73. Villain E, Vetter VL, Garcia JM, et al. Evolving concepts in the man-
agement of congenital junctional ectopic tachycardia: a multicenter
study. Circulation 1990;81:1544–9.
74. Ehlert FA, Goldberger JJ, Deal BJ, et al. Successful radiofrequency
energy ablation of automatic junctional tachycardia preserving normal
atrioventricular nodal conduction. Pacing Clin Electrophysiol 1993;16:
54–61.
75. Hamdan M, Van Hare GF, Fisher W, et al. Selective catheter ablation of
the tachycardia focus in patients with nonre-entrant junctional
tachycardia. Am J Cardiol 1996;78:1292–7.
76. Scheinman MM, Gonzalez RP, Cooper MW, et al. Clinical and electro-
physiologic features and role of catheter ablation techniques in adult
patients with automatic atrioventricular junctional tachycardia. Am J
Cardiol 1994;74:565–72.
77. Castellanos A, Sung RJ, Myerburg RJ. His bundle electrocardiography
in digitalis-induced “atrioventricular junctional” Wenckebach periods
with irregular H-H intervals. Am J Cardiol 1979;43:653–6.
78. Storstein O, Hansteen V, Hatle L, et al. Studies on digitalis: XIII: a
prospective study of 649 patients on maintenance treatment with
digitoxin. Am Heart J 1977;93:434–43.
79. Fisch C. Myocardial infarction: accelerated junctional rhythm. J Indiana
State Med Assoc 1970;63:350.
80. Breslow MJ, Evers AS, Lebowitz P. Successful treatment of accelerated
junctional rhythm with propranolol: possible role of sympathetic stim-
ulation in the genesis of this rhythm disturbance. Anesthesiology 1985;
62:180–2.
81. Dagres N, Clague JR, Lottkamp H, et al. Impact of radiofrequency
catheter ablation of accessory pathways on the frequency of atrial
fibrillation during long-term follow-up; high recurrence rate of atrial
fibrillation in patients older than 50 years of age. Eur Heart J 2001;22:
423–7.
82. Gollob MH, Green MS, Tang AS, et al. Identification of a gene
responsible for familial Wolff-Parkinson-White syndrome. N Engl
J Med 2001;344:1823–31.
83. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden
cardiac death of the European Society of Cardiology. Eur Heart J
2001;22:1374–450.
84. Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive
electrophysiologic testing to stratify the risk of arrhythmic events in
asymptomatic patients with Wolff-Parkinson-White pattern: results from
a large prospective long-term follow-up study. J Am Coll Cardiol 2003;
41:239–44.
85. Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of
accessory atrioventricular pathways (Wolff-Parkinson-White syndrome)
by radiofrequency current. N Engl J Med 1991;324:1605–11.
86. Manolis AS, Katsaros C, Cokkinos DV. Electrophysiological and elec-
tropharmacologic studies in pre-excitation syndromes: results with
propafenone therapy and isoproterenol infusion testing. Eur Heart J
1992;13:1489–95.
87. Zipes DP, DiMarco JP, Gillette PC, et al. Guidelines for clinical intra-
cardiac electrophysiological and catheter ablation procedures: a report of
the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee on Clinical Intracardiac Elec-
trophysiologic and Catheter Ablation Procedures), developed in collab-
oration with the North American Society of Pacing and Electrophys-
iology. J Am Coll Cardiol 1995;26:555–73.
88. Janousek J, Paul T, Reimer A, et al. Usefulness of propafenone for
supraventricular arrhythmias in infants and children. Am J Cardiol
1993;72:294–300.
89. Musto B, D’Onofrio A, Cavallaro C, et al. Electrophysiological effects
and clinical efficacy of propafenone in children with recurrent par-
oxysmal supraventricular tachycardia. Circulation 1988;78:863–9.
90. Vignati G, Mauri L, Figini A. The use of propafenone in the treatment
of tachyarrhythmias in children. Eur Heart J 1993;14:546–50.
91. Vassiliadis I, Papoutsakis P, Kallikazaros I, et al. Propafenone in the
prevention of nonventricular arrhythmias associated with the Wolff-
Parkinson-White syndrome. Int J Cardiol 1990;27:63–70.
92. Helmy I, Scheinman MM, Herre JM, et al. Electrophysiologic effects of
isoproterenol in patients with atrioventricular re-entrant tachycardia
treated with flecainide. J Am Coll Cardiol 1990;16:1649–55.
93. Kim SS, Lal R, Ruffy R. Treatment of paroxysmal re-entrant supraven-
tricular tachycardia with flecainide acetate. Am J Cardiol 1986;58:80–5.
94. Cockrell JL, Scheinman MM, Titus C, et al. Safety and efficacy of oral
flecainide therapy in patients with atrioventricular re-entrant
tachycardia. Ann Intern Med 1991;114:189–94.
95. Hoff PI, Tronstad A, Oie B, et al. Electrophysiologic and clinical effects
of flecainide for recurrent paroxysmal supraventricular tachycardia.
Am J Cardiol 1988;62:585–9.
96. Wiseman MN, Elstob JE, Camm AJ, et al. A study of the use of
flecainide acetate in the long-term management of cardiac arrhythmias.
Pacing Clin Electrophysiol 1990;13:767–75.
97. Benditt DG, Dunnigan A, Buetikofer J, et al. Flecainide acetate for
long-term prevention of paroxysmal supraventricular tachyarrhythmias.
Circulation 1991;83:345–9.
98. Pritchett EL, DaTorre SD, Platt ML, et al., for the Flecainide Supraven-
tricular Tachycardia Study Group. Flecainide acetate treatment of par-
oxysmal supraventricular tachycardia and paroxysmal atrial fibrillation:
dose-response studies. J Am Coll Cardiol 1991;17:297–303.
99. Manolis AS, Estes NA, III. Reversal of electrophysiologic effects of
flecainide on the accessory pathway by isoproterenol in the Wolff-
Parkinson-White syndrome. Am J Cardiol 1989;64:194–8.
100. Kunze KP, Schluter M, Kuck KH. Sotalol in patients with Wolff-
Parkinson-White syndrome. Circulation 1987;75:1050–7.
101. Mason JW. Amiodarone. N Engl J Med 1987;316:455–66.
102. Rosenbaum MB, Chiale PA, Ryba D, et al. Control of tachyarrhythmias
associated with Wolff-Parkinson-White syndrome by amiodarone
hydrochloride. Am J Cardiol 1974;34:215–23.
103. Wellens HJ, Lie KI, Bar FW, et al. Effect of amiodarone in the Wolff-
Parkinson-White syndrome. Am J Cardiol 1976;38:189–94.
104. Kappenberger LJ, Fromer MA, Steinbrunn W, et al. Efficacy of amiod-
arone in the Wolff-Parkinson-White syndrome with rapid ventricular
response via accessory pathway during atrial fibrillation. Am J Cardiol
1984;54:330–5.
105. Lai WT, Voon WC, Yen HW, et al. Comparison of the electrophysi-
ologic effects of oral sustained-release and intravenous verapamil in
patients with paroxysmal supraventricular tachycardia. Am J Cardiol
1993;71:405–8.
106. Calkins H, Sousa J, el Atassi R, et al. Diagnosis and cure of the
Wolff-Parkinson-White syndrome or paroxysmal supraventricular
tachycardias during a single electrophysiologic test. N Engl J Med
1991;324:1612–8.
107. Kuck KH, Schluter M, Geiger M, et al. Radiofrequency current catheter
ablation of accessory atrioventricular pathways. Lancet 1991;337:
1557–61.
108. Calkins H, Langberg J, Sousa J, et al. Radiofrequency catheter ablation
of accessory atrioventricular connections in 250 patients: abbreviated
therapeutic approach to Wolff-Parkinson-White syndrome. Circulation
1992;85:1337–46.
109. Lesh MD, Van Hare GF, Scheinman MM, et al. Comparison of the
retrograde and transseptal methods for ablation of left free wall
accessory pathways. J Am Coll Cardiol 1993;22:542–9.
110. Scheinman MM. NASPE survey on catheter ablation. Pacing Clin Elec-
trophysiol 1995;18:1474–8.
111. Hindricks G, for the Multicentre European Radiofrequency Survey
(MERFS) investigators of the Working Group on Arrhythmias of the
European Society of Cardiology. The Multicentre European Radiofre-
quency Survey (MERFS): complications of radiofrequency catheter
ablation of arrhythmias. Eur Heart J 1993;14:1644–53.
112. Yeh SJ, Lin FC, Chou YY, et al. Termination of paroxysmal supraven-
tricular tachycardia with a single oral dose of diltiazem and propranolol.
Circulation 1985;71:104–9.
113. Saoudi N, Cosio F, Waldo A, et al. A classification of atrial flutter and
regular atrial tachycardia according to electrophysiological mechanisms
and anatomical bases; a statement from a joint expert group from The
Working Group of Arrhythmias of the European Society of Cardiology
and the North American Society of Pacing and Electrophysiology. Eur
Heart J 2001;22:1162–82.
114. Steinbeck G, Hoffmann E. ‘True’ atrial tachycardia. Eur Heart J 1998;19
Suppl E:E10–9.
115. Poutiainen AM, Koistinen MJ, Airaksinen KE, et al. Prevalence and
natural course of ectopic atrial tachycardia. Eur Heart J 1999;20:
694–700.
116. Wren C. Incessant tachycardias. Eur Heart J 1998;19 Suppl E:E32–59.
117. Lee SH, Tai CT, Lin WS, et al. Predicting the arrhythmogenic foci of
atrial fibrillation before atrial transseptal procedure: implication for
catheter ablation. J Cardiovasc Electrophysiol 2000;11:750–7.
1528 Blomström-Lundqvist et al. JACC Vol. 42, No. 8, 2003
ACC/AHA/ESC Guidelines for Management of SVA October 15, 2003:1493–531
118. SippensGroenewegen A, Peeters HA, Jessurun ER, et al. Body surface
mapping during pacing at multiple sites in the human atrium: P-wave
morphology of ectopic right atrial activation. Circulation 1998;97:
369–80.
119. Kalman JM, Olgin JE, Karch MR, et al. “Cristal tachycardias”: origin of
right atrial tachycardias from the crista terminalis identified by intra-
cardiac echocardiography. J Am Coll Cardiol 1998;31:451–9.
120. Tada H, Nogami A, Naito S, et al. Simple electrocardiographic criteria
for identifying the site of origin of focal right atrial tachycardia. Pacing
Clin Electrophysiol 1998;21:2431–9.
121. Hoffmann E, Reithmann C, Nimmermann P, et al. Clinical experience
with electroanatomic mapping of ectopic atrial tachycardia. Pacing Clin
Electrophysiol 2002;25:49–56.
122. Lai LP, Lin JL, Chen TF, et al. Clinical, electrophysiological character-
istics, and radiofrequency catheter ablation of atrial tachycardia near the
apex of Koch’s triangle. Pacing Clin Electrophysiol 1998;21:367–74.
123. Markowitz SM, Stein KM, Mittal S, et al. Differential effects of aden-
osine on focal and macrore-entrant atrial tachycardia. J Cardiovasc
Electrophysiol 1999;10:489–502.
124. Hsieh MH, Chen SA. Catheter ablation of focal AT. In: Zipes DP,
Haissaguerre M, editors. Catheter Ablation of Arrhythmias. Armonk,
NY: Futura Publishing Co., Inc., 2002:185–204.
125. Chen SA, Tai CT, Chiang CE, et al. Focal atrial tachycardia: reanalysis
of the clinical and electrophysiologic characteristics and prediction of
successful radiofrequency ablation. J Cardiovasc Electrophysiol 1998;
9:355–65.
126. Schmitt C, Zrenner B, Schneider M, et al. Clinical experience with a
novel multielectrode basket catheter in right atrial tachycardias. Circu-
lation 1999;99:2414–22.
127. Natale A, Breeding L, Tomassoni G, et al. Ablation of right and left
ectopic atrial tachycardias using a three-dimensional nonfluoroscopic
mapping system. Am J Cardiol 1998;82:989–92.
128. Weiss C, Willems S, Cappato R, et al. High frequency current ablation
of ectopic atrial tachycardia: different mapping strategies for local-
ization of right- and left-sided origin. Herz 1998;23:269–79.
129. Anguera I, Brugada J, Roba M, et al. Outcomes after radiofrequency
catheter ablation of atrial tachycardia. Am J Cardiol 2001;87:886–90.
130. Engelstein ED, Lippman N, Stein KM, et al. Mechanism-specific effects
of adenosine on atrial tachycardia. Circulation 1994;89:2645–54.
131. Harrison DA, Siu SC, Hussain F, et al. Sustained atrial arrhythmias in
adults late after repair of tetralogy of fallot. Am J Cardiol 2001;87:
584–8.
132. Stock JP. Beta adrenergic blocking drugs in the clinical management of
cardiac arrhythmias. Am J Cardiol 1966;18:444–9.
133. Kunze KP, Kuck KH, Schluter M, et a;. Effect of encainide and fle-
cainide on chronic ectopic atrial tachycardia. J Am Coll Cardiol 1986;
7:1121–6.
134. Berns E, Rinkenberger RL, Jeang MK, et al. Efficacy and safety of
flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol
1987;59:1337–41.
135. Coumel P, Leclercq JF, Assayag P. European experience with the
antiarrhythmic efficacy of propafenone for supraventricular and ventric-
ular arrhythmias. Am J Cardiol 1984;54:60D–6D.
136. Lesh MD, Kalman JM, Olgin JE. New approaches to treatment of atrial
flutter and tachycardia. J Cardiovasc Electrophysiol 1996;7:368–81.
137. Beaufort-Krol GC, Bink-Boelkens MT. Sotalol for atrial tachycardias
after surgery for congenital heart disease. Pacing Clin Electrophysiol
1997;20:2125–9.
138. Carrasco HA, Vicuna AV, Molina C, et al. Effect of low oral doses of
disopyramide and amiodarone on ventricular and atrial arrhythmias of
chagasic patients with advanced myocardial damage. Int J Cardiol 1985;
9:425–38.
139. Kopelman HA, Horowitz LN. Efficacy and toxicity of amiodarone for
the treatment of supraventricular tachyarrhythmias. Prog Cardiovasc Dis
1989;31:355–66.
140. Prager NA, Cox JL, Lindsay BD, et al. Long-term effectiveness of
surgical treatment of ectopic atrial tachycardia. J Am Coll Cardiol
1993;22:85–92.
141. Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in
adult patients: electrophysiological characteristics, pharmacologic
response, possible mechanisms, and effects of radiofrequency ablation.
Circulation 1994;90:1262–78.
142. Creamer JE, Nathan AW, Camm AJ. Successful treatment of atrial
tachycardias with flecainide acetate. Br Heart J 1985;53:164–6.
143. Pool PE, Quart BD. Treatment of ectopic atrial arrhythmias and pre-
mature atrial complexes in adults with encainide. Am J Cardiol 1988;
62:60L–2L.
144. Cheng J, Scheinman MM. Acceleration of typical atrial flutter due to
double-wave re-entry induced by programmed electrical stimulation.
Circulation 1998;97:1589–96.
145. Cheng J, Cabeen WR Jr., Scheinman MM. Right atrial flutter due to
lower loop re-entry: mechanism and anatomic substrates. Circulation
1999;99:1700–5.
146. Yang Y, Cheng J, Bochoeyer A, et al. Atypical right atrial flutter
patterns. Circulation 2001;103:3092–8.
147. Friedman PA, Luria D, Fenton AM, et al. Global right atrial mapping of
human atrial flutter: the presence of posteromedial (sinus venosa region)
functional block and double potentials: a study in biplane fluoroscopy
and intracardiac echocardiography. Circulation 2000;101:1568–77.
148. Li W, Somerville J. Atrial flutter in grown-up congenital heart (GUCH)
patients: clinical characteristics of affected population. Int J Cardiol
2000;75:129–37.
149. Puley G, Siu S, Connelly M, et al. Arrhythmia and survival in patients
18 years of age after the mustard procedure for complete transposition
of the great arteries. Am J Cardiol 1999;83:1080–4.
150. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and
safety of intravenous ibutilide compared with intravenous procainamide
in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31:
1414–9.
151. Vos MA, Golitsyn SR, Stangl K, et al., for the Ibutilide/Sotalol Com-
parator Study Group. Superiority of ibutilide (a new class III agent) over
DL-sotalol in converting atrial flutter and atrial fibrillation. Heart 1998;
79:568–75.
152. Doni F, Manfredi M, Piemonti C, et al. New onset atrial flutter termi-
nation by overdrive transoesophageal pacing: effects of different pro-
tocols of stimulation. Europace 2000;2:292–6.
153. Rostas L, Antal K, Putorek Z. Transesophageal pacemaker therapy in
atrial flutter after procainamide pretreatment. Am J Ther 1999;6:
237–40.
154. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide
in converting to and maintaining sinus rhythm in patients with chronic
atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation
investigative research on dofetilide (SAFIRE-D) study. Circulation
2000;102:2385–90.
155. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the
treatment of atrial fibrillation-flutter in patients with reduced left ven-
tricular function: a Danish investigations of arrhythmia and mortality on
dofetilide (diamond) substudy. Circulation 2001;104:292–6.
156. Benditt DG, Williams JH, Jin J, et al., for the d,l-Sotalol Atrial Fibril-
lation/Flutter Study Group. Maintenance of sinus rhythm with oral
d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or
atrial flutter. Am J Cardiol 1999;84:270–7.
157. Dunn MI. Thrombolism with atrial flutter. Am J Cardiol 1998;82:638.
158. Seidl K, Hauer B, Schwick NG, et al. Risk of thromboembolic events in
patients with atrial flutter. Am J Cardiol 1998;82:580–3.
159. Weiss R, Marcovitz P, Knight BP, et al. Acute changes in spontaneous
echo contrast and atrial function after cardioversion of persistent atrial
flutter. Am J Cardiol 1998;82:1052–5.
160. Sparks PB, Jayaprakash S, Vohra JK, et al. Left atrial “stunning”
following radiofrequency catheter ablation of chronic atrial flutter. J Am
Coll Cardiol 1998;32:468–75.
161. Lip GY, Kamath S. Thromboprophylaxis for atrial flutter. Eur Heart J
2001;22:984–7.
162. Willems S, Weiss C, Ventura R, et al. Catheter ablation of atrial flutter
guided by electroanatomic mapping (CARTO): a randomized com-
parison to the conventional approach. J Cardiovasc Electrophysiol 2000;
11:1223–30.
163. Kottkamp H, Hugl B, Krauss B, et al. Electromagnetic versus fluoro-
scopic mapping of the inferior isthmus for ablation of typical atrial
flutter: a prospective randomized study. Circulation 2000;102:2082–6.
164. Natale A, Newby KH, Pisano E, et al. Prospective randomized com-
parison of antiarrhythmic therapy versus first-line radiofrequency
ablation in patients with atrial flutter. J Am Coll Cardiol 2000;35:
1898–904.
165. Schumacher B, Jung W, Lewalter T, et al. Radiofrequency ablation of
atrial flutter due to administration of class IC antiarrhythmic drugs for
atrial fibrillation. Am J Cardiol 1999;83:710–3.
166. Tai CT, Chiang CE, Lee SH, et al. Persistent atrial flutter in patients
treated for atrial fibrillation with amiodarone and propafenone: electro-
1529JACC Vol. 42, No. 8, 2003 Blomström-Lundqvist et al.
October 15, 2003:1493–531 ACC/AHA/ESC Guidelines for Management of SVA
physiologic characteristics, radiofrequency catheter ablation, and risk
prediction. J Cardiovasc Electrophysiol 1999;10:1180–7.
167. Nabar A, Rodriguez LM, Timmermans C, et al. Radiofrequency ablation
of “class IC atrial flutter” in patients with resistant atrial fibrillation.
Am J Cardiol 1999;83:785–7.
168. Reithmann C, Hoffmann E, Spitzlberger G, et al. Catheter ablation of
atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation.
Eur Heart J 2000;21:565–72.
169. Huang DT, Monahan KM, Zimetbaum P, et al. Hybrid pharmacologic
and ablative therapy: a novel and effective approach for the management
of atrial fibrillation. J Cardiovasc Electrophysiol 1998;9:462–9.
170. VanderLugt JT, Mattioni T, Denker S, et al. Efficacy and safety of
ibutilide fumarate for the conversion of atrial arrhythmias after cardiac
surgery. Circulation 1999;100:369–75.
171. Delle KG, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem
for rate control in critically ill patients with atrial tachyarrhythmias. Crit
Care Med 2001;29:1149–53.
172. Nakagawa H, Shah N, Matsudaira K, et al. Characterization of re-entrant
circuit in macrore-entrant right atrial tachycardia after surgical repair of
congenital heart disease: isolated channels between scars allow “focal”
ablation. Circulation 2001;103:699–709.
173. Shah D, Jais P, Takahashi A, et al. Dual-loop intra-atrial re-entry in
humans. Circulation 2000;101:631–9.
174. Triedman JK, Alexander ME, Berul CI, et al. Electroanatomic mapping
of entrained and exit zones in patients with repaired congenital heart
disease and intra-atrial re-entrant tachycardia. Circulation 2001;103:
2060–5.
175. Triedman JK, Saul JP, Weindling SN, et al. Radiofrequency ablation of
intra-atrial re-entrant tachycardia after surgical palliation of congenital
heart disease. Circulation 1995;91:707–14.
176. Akar JG, Kok LC, Haines DE, et al. Coexistence of type I atrial flutter
and intra-atrial re-entrant tachycardia in patients with surgically cor-
rected congenital heart disease. J Am Coll Cardiol 2001;38:377–84.
177. Chan DP, Van Hare GF, Mackall JA, et al. Importance of atrial flutter
isthmus in postoperative intra-atrial re-entrant tachycardia. Circulation
2000;102:1283–9.
178. Delacretaz E, Ganz LI, Soejima K, et al. Multi atrial macro-re-entry
circuits in adults with repaired congenital heart disease: entrainment
mapping combined with three-dimensional electroanatomic mapping.
J Am Coll Cardiol 2001;37:1665–76.
179. Duru F, Hindricks G, Kottkamp H. Atypical left atrial flutter after
intraoperative radiofrequency ablation of chronic atrial fibrillation: suc-
cessful ablation using three-dimensional electroanatomic mapping.
J Cardiovasc Electrophysiol 2001;12:602–5.
180. Thomas SP, Nunn GR, Nicholson IA, et al. Mechanism, localization and
cure of atrial arrhythmias occurring after a new intraoperative endo-
cardial radiofrequency ablation procedure for atrial fibrillation. J Am
Coll Cardiol 2000;35:442–50.
181. Hebe J, Hansen P, Ouyang F, et al. Radiofrequency catheter ablation of
tachycardia in patients with congenital heart disease. Pediatr Cardiol
2000;21:557–75.
182. Kall JG, Rubenstein DS, Kopp DE, et al. Atypical atrial flutter origi-
nating in the right atrial free wall. Circulation 2000;101:270–9.
183. Molenschot M, Ramanna H, Hoorntje T, et al. Catheter ablation of
incisional atrial tachycardia using a novel mapping system: LocaLisa.
Pacing Clin Electrophysiol 2001;24:1616–22.
184. Jais P, Shah DC, Haissaguerre M, et al. Mapping and ablation of left
atrial flutters. Circulation 2000;101:2928–34.
185. Tai CT, Lin YK, Chen SA. Atypical atrial flutter involving the isthmus
between the right pulmonary veins and fossa ovalis. Pacing Clin Elec-
trophysiol 2001;24:384–7.
186. Tucker KJ, Wilson C. A comparison of transoesophageal atrial pacing
and direct current cardioversion for the termination of atrial flutter: a
prospective, randomised clinical trial. Br Heart J 1993;69:530–5.
187. Doni F, Della BP, Kheir A, et al. Atrial flutter termination by overdrive
transesophageal pacing and the facilitating effect of oral propafenone.
Am J Cardiol 1995;76:1243–6.
188. Doni F, Staffiere E, Manfredi M, et al. Type II atrial flutter interruption
with transesophageal pacing: use of propafenone and possible change of
the substrate. Pacing Clin Electrophysiol 1996;19:1958–61.
189. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967;
29:469–89.
190. Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC
antiarrhythmic drugs for acute conversion of paroxysmal atrial fibril-
lation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722–7.
191. Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial
fibrillation and flutter: the role of flecainide, propafenone, and verap-
amil. Am J Cardiol 1992;70:56A–60A.
192. Stambler BS, Wood MA, Ellenbogen KA, et al., for the Ibutilide Repeat
Dose Study Investigators. Efficacy and safety of repeated intravenous
doses of ibutilide for rapid conversion of atrial flutter or fibrillation.
Circulation 1996;94:1613–21.
193. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous
ibutilide for rapid termination of atrial fibrillation and atrial flutter: a
dose-response study. J Am Coll Cardiol 1996;28:130–6.
194. Sung RJ, Tan HL, Karagounis L, et al., for the Sotalol Multicenter Study
Group. Intravenous sotalol for the termination of supraventricular
tachycardia and atrial fibrillation and flutter: a multicenter, randomized,
double-blind, placebo-controlled study. Am Heart J 1995;129:739–48.
195. Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset
atrial fibrillation and flutter with a tailored dosing regimen of intrave-
nous amiodarone: a randomized, digoxin-controlled study. Eur Heart J
1995;16:521–8.
196. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial
fibrillation and flutter: intravenous diltiazem versus intravenous digoxin.
Ann Emerg Med 1997;29:135–40.
197. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verap-
amil in the acute treatment of atrial fibrillation or atrial flutter. Am J
Cardiol 1989;63:925–9.
198. Goldenberg IF, Lewis WR, Dias VC, et al. Intravenous diltiazem for the
treatment of patients with atrial fibrillation or flutter and moderate to
severe congestive heart failure. Am J Cardiol 1994;74:884–9.
199. Chen SA, Chiang CE, Wu TJ, et al. Radiofrequency catheter ablation of
common atrial flutter: comparison of electrophysiologically guided focal
ablation technique and linear ablation technique. J Am Coll Cardiol
1996;27:860–8.
200. Naccarelli GV, Dorian P, Hohnloser SH, et al, for the Flecainide Mul-
ticenter Atrial Fibrillation Study Group. Prospective comparison of
flecainide versus quinidine for the treatment of paroxysmal atrial fibril-
lation/flutter. Am J Cardiol 1996;77:53A–9A.
201. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for
the management of patients with atrial fibrillation: a report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines and the European Society of Cardiology
Committee for Practice Guidelines and Policy Conferences (Committee
to Develop Guidelines for the Management of Patients With Atrial
Fibrillation), developed in collaboration with the North American
Society of Pacing and Electrophysiology. Eur Heart J 2001;22:
1852–923.
202. Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy:
safety considerations. Drug Saf 1999;20:85–94.
203. Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus
radiation dose and risk from cardiac catheter ablation procedures. Cir-
culation 2001;104:893–7.
204. Lydakis C, Lip GY, Beevers M, et al. Atenolol and fetal growth in
pregnancies complicated by hypertension. Am J Hypertens 1999;12:
541–7.
205. Simpson JM, Sharland GK. Fetal tachycardias: management and
outcome of 127 consecutive cases. Heart 1998;79:576–81.
206. Bartalena L, Bogazzi F, Braverman LE, et al. Effects of amiodarone
administration during pregnancy on neonatal thyroid function and sub-
sequent neurodevelopment. J Endocrinol Invest 2001;24:116–30.
207. Gatzoulis MA, Freeman MA, Siu SC, et al. Atrial arrhythmia after
surgical closure of atrial septal defects in adults. N Engl J Med 1999;
340:839–46.
208. Attie F, Rosas M, Granados N, et al. Surgical treatment for secundum
atrial septal defects in patients 40 years old: a randomized clinical
trial. J Am Coll Cardiol 2001;38:2035–42.
209. Donti A, Bonvicini M, Placci A, et al. Surgical treatment of secundum
atrial septal defect in patients older than 50 years. Ital Heart J 2001;2:
428–32.
210. Triedman JK, Alexander ME, Love BA, et al. Influence of patient
factors and ablative technologies on outcomes of radiofrequency
ablation of intra-atrial re-entrant tachycardia in patients with congenital
heart disease. J Am Coll Cardiol 2002;39:1827–35.
211. Gatzoulis MA, Walters J, McLaughlin PR, et al. Late arrhythmia in
adults with the mustard procedure for transposition of great arteries: a
surrogate marker for right ventricular dysfunction? Heart 2000;84:
409–15.
1530 Blomström-Lundqvist et al. JACC Vol. 42, No. 8, 2003
ACC/AHA/ESC Guidelines for Management of SVA October 15, 2003:1493–531
212. Sarkar D, Bull C, Yates R, et al. Comparison of long-term outcomes of
atrial repair of simple transposition with implications for a late arterial
switch strategy. Circulation 1999;100:II176–81.
213. Li W, Somerville J, Gibson DG, et al. Disturbed atrioventricular elec-
tromechanical function long after Mustard operation for transposition of
great arteries: a potential contributing factor to atrial flutter. J Am Soc
Echocardiogr 2001;14:1088–93.
214. Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia
and sudden cardiac death late after repair of tetralogy of Fallot: a
multicentre study. Lancet 2000;356:975–81.
215. Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve
replacement on arrhythmia propensity late after repair of tetralogy of
Fallot. Circulation 2001;103:2489–94.
216. Natterson PD, et al. Electrophysiologic abnormalities: unoperated
occurrence and postoperative residua and sequelae. In: Perloff J, Child
JS, eds. Congenital heart disease in adults. Philadelphia, PA: WB
Saunders, 1998:316–39.
217. Hebe J. Ebstein’s anomaly in adults arrhythmias: diagnosis and thera-
peutic approach. Thorac Cardiovasc Surg 2000;48:214–9.
218. Ho SY, Goltz D, McCarthy K, et al. The atrioventricular junctions in
Ebstein malformation. Heart 2000;83:444–9.
219. Attie F, Rosas M, Rijlaarsdam M, et al. The adult patient with Ebstein
anomaly: outcome in 72 unoperated patients. Medicine (Baltimore)
2000;79:27–36.
220. Huang CJ, Chiu IS, Lin FY, et al. Role of electrophysiological studies
and arrhythmia intervention in repairing Ebstein’s anomaly. Thorac
Cardiovasc Surg 2000;48:347–50.
221. Reich JD, Auld D, Hulse E, et al., for the Pediatric Electrophysiology
Society. The Pediatric Radiofrequency Ablation Registry’s experience
with Ebstein’s anomaly. J Cardiovasc Electrophysiol 1998;9:1370–7.
222. Gatzoulis MA, Munk MD, Williams WG, et al. Definitive palliation
with cavopulmonary or aortopulmonary shunts for adults with single
ventricle physiology. Heart 2000;83:51–7.
223. Ghai A, Harris L, Harrison DA, et al. Outcomes of late atrial
tachyarrhythmias in adults after the Fontan operation. J Am Coll Cardiol
2001;37:585–92.
224. Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter
ablation of atrial arrhythmias: results and mechanisms. Circulation 1994;
89:1074–89.
225. Triedman JK, Jenkins KJ, Colan SD, et al. Intra-atrial re-entrant
tachycardia after palliation of congenital heart disease: characterization
of multiple macrore-entrant circuits using fluoroscopically based three-
dimensional endocardial mapping. J Cardiovasc Electrophysiol 1997;8:
259–70.
226. Misaki T, Watanabe G, Iwa T, et al. Surgical treatment of patients with
Wolff-Parkinson-White syndrome and associated Ebstein’s anomaly.
J Thorac Cardiovasc Surg 1995;110:1702–7.
227. Bubien RS, Knotts-Dolson SM, Plumb VJ, et al. Effect of radiofre-
quency catheter ablation on health-related quality of life and activities of
daily living in patients with recurrent arrhythmias. Circulation 1996;94:
1585–91.
228. Lau CP, Tai YT, Lee PW. The effects of radiofrequency ablation versus
medical therapy on the quality-of-life and exercise capacity in patients
with accessory pathway-mediated supraventricular tachycardia: a
treatment comparison study. Pacing Clin Electrophysiol 1995;18:
424–32.
229. Bathina MN, Mickelsen S, Brooks C, et al. Radiofrequency catheter
ablation versus medical therapy for initial treatment of supraventricular
tachycardia and its impact on quality of life and healthcare costs. Am J
Cardiol 1998;82:589–93.
230. Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radio-
frequency ablation for supraventricular tachycardia. Ann Intern Med
2000;133:864–76.
231. Goldberg AS, Bathina MN, Mickelsen S, et al. Long-term outcomes on
quality-of-life and health care costs in patients with supraventricular
tachycardia (radiofrequency catheter ablation versus medical therapy).
Am J Cardiol 2002;89:1120–3.
232. Anselme F, Saoudi N, Poty H, et al. Radiofrequency catheter ablation of
common atrial flutter: significance of palpitations and quality-of-life
evaluation in patients with proven isthmus block. Circulation 1999;99:
534–40.
233. Lee SH, Tai CT, Yu WC, et al. Effects of radiofrequency catheter
ablation on quality of life in patients with atrial flutter. Am J Cardiol
1999;84:278–83.
234. O’Callaghan PA, Meara M, Kongsgaard E, et al. Symptomatic
improvement after radiofrequency catheter ablation for typical atrial
flutter. Heart 2001;86:167–71.
KEY WORDS: ACC/AHA/ESC Practice Guidelines  arrhythmia 
tachycardia  ablation  drugs
1531JACC Vol. 42, No. 8, 2003 Blomström-Lundqvist et al.
October 15, 2003:1493–531 ACC/AHA/ESC Guidelines for Management of SVA
